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I. Abstract
GENETICS OF VEIN OF GALEN MALFORMATION AND ASSESSMENT OF
CANDIDATE GENES IN XENOPUS TROPICALIS
Jonathan R. Gaillard, Daniel D. Duran, Mustafa Khokha, Engin Deniz, and Kristopher T.
Kahle. Section of Pediatric Neurosurgery, Department of Neurosurgery, Yale University,
School of Medicine, New Haven, CT.

The Vein of Galen Malformation (VOGM) is a specific subtype of arteriovenous
malformation (AVM) that becomes evident in weeks 6-11 of embryonic development.
VOGM comprise less than 1% of all vascular malformations, yet represent 30% of all
pediatric intracranial vascular malformations. Depending on their specific characteristics,
i.e. its feeding vessels, it can present clinically as devastating congestive heart failure in
neonates, hydrocephalus in children, or seizures and headaches in young adults. Advances
in treatment provide improved survival, primarily through endovascular surgery. The
genetic and molecular etiology of VOGM remains relatively unknown, with the only
associated genes being in the context of other syndromes, including seven mutations in
p120-RasGAP (RASA1) in Cutaneous Malformations-Arteriovenous Malformations (CMAVM), as well as one mutation each in activin A receptor type II-like 1 (ACVRL1) mutation
and Endoglin (ENG) in Hereditary Hemorraghic Teleangiectasia.

Our limited knowledge of the molecular genetics of VOGM has hindered the development
of novel therapies. We hypothesized that the apparent sporadic occurrence of VOGM may
frequently be attributable to damaging de novo mutation events or incomplete penetrance

of rare transmitted variants. Unbiased whole-exome sequencing (WES) can overcome
these barriers for gene discovery. We recruited 55 patients, including 52 parent-offspring
trios. WES revealed statistically significant rare, damaging de novo mutations in chromatin
modifier genes involved in brain and vascular development (p=8.9 x 10-4). VOGM
probands also had inherited, missense deleterious and loss of function, in ephrin signaling
genes, specifically a whole exome significant mutation burden in EPHB4 (p=7.47 x 10−10).
Finally, we observed a whole exome significant inherited mutation in Claudin 14 (p= 6.44
x 10−7). Inherited mutations demonstrated incomplete penetrance and variable expressivity
with mutation carriers often exhibiting cutaneous vascular abnormalities suggesting a twohit mechanism. The identified mutations account for 30% of studied VOGM cases.

To functionally validate candidate mutations and establish causality, we developed a
screening platform using Xenopus tropicalis by using CRISP/Cas9 gene editing and
observing the effects of candidate gene knockdown on vasculogenesis and brain
vasculature.

CRISPR/Cas9 knockdown of EPHB4 and CLDN14 yielded significantly abnormal
vasculogenesis (p=0.0028 and p=0.0001 respectively) observed by in situ hybridization.
We implemented and modified established clearing techniques to allow visualization of the
full thickness of the Xenopus brain vasculature. The evolutionary precursor to the vein of
Galen, the posterior vascular plexus (PVP), and the mesencephalic veins (MSV), were
imaged. EPHB4 and CLDN14 CRISPR/Cas9 knockdown revealed significant decreases in
MSV length (p<0.0001 and p=0.0006 respectively) but there was no significant decrease

in PVP area. Attempted rescue with wild-type vs. mutant human CLDN14 mRNA did not
lead to significant improvement of the phenotype.

Together these findings are the first step in better understanding the mechanism and
pathogenesis of VOGM and potential novel therapeutic targets. While Xenopus is not a
perfect model system, it does show promise as a tool to assess candidate VOGM that merit
further study in mammalian systems harboring a true vein of Galen.
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IV. Introduction to Vein of Galen Malformations
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IV. Introduction to Vein of Galen Malformations
Please note, some of the text below includes figures and text, taken and adapted from the
article:
Duran, D., Karschnia, P., Gaillard, J.R., Karimy, J.K., Youngblood, M.W., DiLuna, M.L.,
Matouk, C.C., Aagaard-Kienitz, B., Smith, E.R., Orbach, D.B., Rodesch, G., Berenstein,
A., Gunel, M., & Kahle, K.T. Human Genetics and molecular mechanisms of vein of
Galen malformation. J Neurosurg Pediatr. 2018 Apr;21(4):367-374.
It is reproduced here with permission from Journal of Neurosurgery.
The Vein of Galen Malformation (VOGM) is a specific type of Arteriovenous
Malformation (AVM) that offers a unique opportunity to understand the pathogenesis of
AVMs providing insight into disease causing mutations in arterio-venous differentiation.
Although it is estimated that VOGM makes up only 1% of all intracranial vascular
malformations, VOGM represent 30% of all pediatric intracranial vascular malformations
(Deloison et al., 2012; Long et al., 1974). VOGM starts in weeks 6-11 of embryonic
development (Raybaud et al., 1989). VOGM are phenotypically varied in their presentation
depending on their feeding vessels. In severe cases, the VOGM can be detected in utero by
ultrasound and can present clinically as devastating congestive heart failure in neonates, or
in less severe cases present with hydrocephalus in children, or seizures and headaches in
young adults (Amacher and Shillito, 1973). VOGM rarely present with stroke and do not
rupture, thereby leading to improved outcomes through diagnosis and treatment. The study
of the genetics of VOGM will prove invaluable to the study of other AVMs by unveiling
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pathways and mechanisms that are responsible for dysregulated arterio-venous
differentiation.

Advances in treatments provide improved survival, primarily through endovascular
surgery, and less frequently, radiosurgery (Lasjaunias et al., 1995; Lasjaunias et al., 2006).
Previously, with clipping and microsurgery mortality was 80-100%, however,
endovascular surgery greatly reduced mortality to 15% (Khullar et al., 2010). However,
the genetic and molecular etiology of VOGM remains relatively unknown, limiting the
creation of novel therapies that may further reduce mortality and morbidity by intervening
at even earlier. At present, the fundamental lack of information regarding the genetic and
molecular etiology of VOGM leaves physicians unprepared for the increased population
of VOGM patients, some of whom will likely be born to parents who themselves were
treated for VOGM.

Here we review the pathophysiology, diagnosis, and management of infants and children
with VOGM and the limited genetic landscape. We examine studies on arteriovenous
malformations, specifically the arteriovenous specification and in model organisms. A
comprehensive understanding of the key genetic drivers and the associated molecular
mechanisms of VOGM may identify targets for the development of novel
pharmacotherapeutic strategies, if not genetic counseling for VOGM patients who will one
day have families of their own.
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The pathophysiology of VOGM/ Importance of Brain AVMs and VOGM
Brain AVMs occur in approximately 1.3/100,000 person-years (Gabriel et al., 2010).
VOGM themselves represent <1% of all vascular malformations yet account for
approximately 30% of all pediatric cerebrovascular malformations (Deloison et al., 2012;
Long et al., 1974). Jaeger and colleagues reported the first VOGM patient (Jaeger et al.,
1937), a 4-year-old child who presented at 8 months of age with hydrocephalus due to the
vein of Galen occluding the sylvian aqueduct (Jaeger et al., 1937).

The development of VOGM was still largely debated until the late 1980s. Raybaud and
colleagues (Raybaud et al., 1989) found that between gestational weeks 6 and 11 the
affected embryo develops arteriovenous fistulas that feed into the embryonic structure
named the median prosencephalic vein of Markowski. The arteriovenous fistula creates a
persistent turbulent flow which prevents the natural regression of the median vein and
thereby maintains the patency of the median prosencephalic vein which enlarges in size
and occupies the same location as the vein of Galen (Raybaud et al., 1989). This creates a
misnomer as the VOGM does not actually affect the vein of Galen proper.

VOGMs fall into two distinct angioarchitectural patterns: choridal (Fig. 1A) and mural
(Fig. 1B). Choridal malformations are characterized by numerous feeder vessels and
“pseudoniduses” that communicate with the medial prosencephalic vein. In contrast, mural
VOGMs present a small number of larger-caliber fistulas into this structure (Lasjaunias et
al., 2006). One or more arteries can directly feed into the median prosencephalic vein and
certain arteries are found in different classes of VOGM. The arteries include the posterior
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choroidal artery, anterior cerebral artery (neonates>child), middle cerebral artery
(neonates>>child), anterior choroidal arteries (neonates only), anterior thalamoperforate
arteries, or branches of the middle meningeal arteries (Raybaud et al., 1989). Care must be
taken to differentiate true VOGMs, which arise from the median prosencephalic vein, from
AVMs that drain into a dilated but already formed vein of Galen, specifically named Vein
of Galen Dilitations (VGAD) (Lasjaunias et al., 1987).

In the natural history of the disease, patients are phenotypically variable in their
presentation. Significant cerebral damage or multiorgan damage are contraindications to
pursuing intervention (de Koning et al., 1997; Rodesch et al., 1994; Swanstrom et al., 1994;
Yuval et al., 1997). Patients who present in the neonatal period present high-output cardiac
failure, which is fatal without intervention within days or weeks of birth (Amacher and
Shillito, 1973; Hoffman et al., 1982; Johnston et al., 1987). Patients who fail medical
management in the neonatal period undergo emergent endovascular embolization. Unlike
in traditional AVMs, VOGM rarely present with hemorrhage (Suh et al., 2001). In a series
of 34 patients, two with mural lesions and one with a choroidal lesion developed
hemorrhage; with one presenting with subarachnoid hemorrhage at 19 hours of age, one
with acute intraventricular hemorrhage at 5 months of age, and the third due to intraoperative complication causing intraventricular hemorrhage (Meyers et al., 2000). Another
patient had a subdural hemorrhage and intracerebral hemorrhage as an unforeseen
consequence to a shunting procedure (Suh et al., 2001). Other case series have also noted
few hemorrhages (Halbach et al., 1998).
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Patients who are medically managed or asymptomatic at birth, or those who do not receive
definitive treatment can undergo continued, and unless acted upon, permanent, changes to
the vascular and ventricular systems of the brain. Many patients experience hydrocephalus
and a large retrospective series found hydrocephalus as the second most common
presenting symptom, 46.8% of all patients with a greater preponderance in infants (73%)
as compared to children, adults (30%), or neonates (15%) (Zerah et al., 1992). Similar
percentages have been reported in other cases (17/22) (Amacher and Shillito, 1973). The
development of hydrocephalus is likely due to the elevated pressure in the venous sinuses,
preventing the normal reabsorption of CSF (Mickle et al., 1994; Zerah et al., 1992).
However, some patients develop persistent venous insufficiency which has resulted in
hydrocephalus, progressive atrophy, and parenchymal calcification in what has been
termed “brain melting” by some (Brunelle, 1997; Lasjaunias, 1997). It has been postulated
that attempts to manage the hydrocephalus accelerates parenchymal deterioration by
reversing flow in the medullary veins from a cerebro-fugal direction to a cerebro-petal one,
thus decreasing parenchymal perfusion and leading to parenchymal deterioration
(Brunelle, 1997; Lasjaunias, 1997; Zerah et al., 1992). Other VOGM patients develop
seizures (Hoffman et al., 1982), and VOGM presents in teenagers and adults as persistent
headaches. There is one report of a VOGM rupturing in a 62-year-old woman (Tsai et al.,
2015).

Since the report of the first patient with a VOGM in 1937, there have been several
classification systems for VOGM patients based on their age and presenting features
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(Amacher and Shillito, 1973; Gold et al., 1964) and a score for clinical management and
whether or not intervention would have any merits (Lasjaunias et al., 2006).

Gold and colleagues created the first classification system with three groups: neonates with
cardiac insufficiency, infants and young children with hydrocephalus and convulsions, and
older children to adults with headaches and subarachnoid hemorrhage (Gold et al., 1964).
Amacher and Shilito added a fourth category to the system and created more specific
criteria (Amacher and Shillito, 1973). Group 1 presented at during the neonatal period with
severe cardiac failure and cranial bruit, Group 2 was a mix of patients that presented in
neonatal or infancy period with mild heart failure, craniomegaly within 1-6 month of birth,
and cranial bruit (Amacher and Shillito, 1973). Group 3 presented in infancy (1-12 months
of age) with craniomegaly and cranial bruit while Group 4 presented late (>3 years) with
headache, exercise syncope, and calcified rim in pineal regions (Amacher and Shillito,
1973).

Lasjaunias published the experience at L’ Hôpital Bicêtre with examining 317 and treating
223 VOGM patients from 1981 to 2002 (Lasjaunias, 2003), and later refined it into the
Bicêtre score, a clinical scoring system to determine management particularly neonates
(Lasjaunias et al., 2006). The max score of 21 is based on five categories: cardiac (5 points),
cerebral (5 points), respiratory (5 points), hepatic (3 points), and renal (3 points) function,
examining effectiveness of medications, seizures, required respiratory support, and urine
output (Lasjaunias et al., 2006). The score helps guide neonatal and infant management
such as the decision to forgo treatment in patients with severe brain or multiorgan damage
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(score <8), and the need for emergent embolization in patients who fail medical
management (Lasjaunias, 2003; Lasjaunias et al., 2006).

Diagnosis of VOGM
While many tests have been used to evaluate suspected VOGM in the past, including
auscultation for cranial bruit, skull film, cardiac catheter, air contrast, and 99m TC scan
angiogram was the most conclusive (Fig. 1A,B) (Amacher and Shillito, 1973). More
recently, Magnetic resonance angiogram and CT angiogram (Fig. 1C,D) have been used
to both diagnose and plan for embolization.

Early diagnosis is important for the management of the newborn with VOGM in case
urgent endovascular therapy is needed. Pre-natal ultrasound can assist with early detection
of VOGM to gather the appropriate resources for the management of the newborn. The 20year experience of one center demonstrated that 40-50% of VOGM are diagnosed in utero
(Lasjaunias, 2003). Other studies have shown similar numbers with 4/13 patients another
series that were diagnosed prenatally (Jones et al., 2002). In utero MRI can also assist with
classification of VOGM subtype and management decisions (Fig. 1E,F) (Breysem et al.,
2003; Huisman et al., 2002). MRI and MRA of a mother pregnant with a VOGM fetus at
31weeks 4 days revealed severely dilated dural venous sinuses, intracranial veins, cerebral
ventriculomegaly, periventricular white matter injury with hemorrhage, global
cardiomegaly, fetal hydrops, and polyhydramnios (Wagner et al., 2015).
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Occasionally, prenatally diagnosed patients require early delivery, whether it be due to fetal
demise or for more effective cardiac evaluation and management (Doren et al., 1995; Yuval
et al., 1997). In utero evidence of cardiac dysfunction is a poor prognosis (Yuval et al.,
1997). Patients that are stable enough in the neonatal period, can undergo less invasive
imaging techniques to plan for surgery at a later date.

Treatment and outcomes of VOGM
Treatment of VOGM was limited until the use of radiosurgery and endovascular therapy.
Surgical clipping led to 100% mortality with minimal improvement to 80% with the advent
of microsurgery (Khullar et al., 2010). During this period, most patients died postoperatively. It was not until radiosurgery, and more specifically embolization, that
significantly improved survival. This was further improved by changing from a transveous
(Casasco et al., 1991), to an arterial approach (Lasjaunias et al., 1991). One case series of
14 patients spanned the transition from clipping to endovascular techniques (Ciricillo et
al., 1990). Ciricillo et al. treated five infants between 1978-1983 with craniotomy and
clipping of feeding vessels, all of whom died perioperatively, while six of eight neonates
who underwent endovascular intervention survived (Ciricillo et al., 1990).

Over time came improvements with experience, patient selection, medical management,
timing of interventions, and institutional preparedness. At first, endovascular therapy was
efficient for infants and children, however it still had a high rate of morbidity and mortality
in the neonatal period with mortality ranging from 23-75% and morbidity 21-88% in
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several series (Brunelle, 1997; Casasco et al., 1991; Lasjaunias et al., 1995; Lasjaunias et
al., 1989; Lylyk et al., 1993).

Although embolization can be performed in the neonatal period when intensive cardiac
management fails, it has better outcomes when delayed until at least 5 months of age
(Lasjaunias, 2003). Embolization is also performed in cases where the patient deteriorates
whether due to seizures, failure to thrive, worsening cardiac failure, or developmental delay
(Bhattacharya and Thammaroj, 2003). The delay in first embolization allows the infant to
grow to better tolerate surgery, vessels to increase in size, and for the cerebral vasculature
to mature, thereby reducing the risk of adverse side effects of treatment. Additionally,
complete occlusion of the shunt has led to poor outcomes as the immature cerebral
vasculature does not tolerate the dramatic increase in blood volume and pressure after the
shunt is closed (Jones et al., 2002). Using a series of 2-3 surgeries, the VOGM is closed,
with the target of a 1/3 reduction of the shunt in the first procedure (Lasjaunias, 2003;
Lasjaunias et al., 2006).

These improvements led to significant reductions in mortality with survival of 90% in the
216 cases that underwent embolization, with 74% of children neurologically normal,
15.6% with a mild-moderate deficit or delay, and 10.4% with significant delay or deficit
(Lasjaunias, 2003). Other institutions have reported similar decreases in mortality with
~80% survival (Li et al., 2011; Mitchell et al., 2001). Morbidity has also improved
alongside mortality. Most patients survive with little or no neurological impairment after
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treatment with rates 66.7% (Li et al., 2011), 67% (Rodesch et al., 1994) and others
(Mitchell et al., 2001) reporting similar rates.

Today neonates and infants remain disproportionately affected, with one third having no
or little impairment, one third having moderate neurological impairment, and one third
having severe, devastating neurological impairment or death (Khullar et al., 2010).
Centralized care has become crucial as well to appropriate treatment. The implementation
of a multidisciplinary team involving obstetrics, cardiology, neonatology, neurosurgery,
and others, as well as appropriate diagnostic and therapeutic strategies, from prenatal
detection to timing of the intervention, has also improved patient outcomes (Berenstein et
al., 2012). The implementation of such a strategy at a single, high-volume center, has
reduced neonatal mortality rate from 50% to 11% in less than 2 decades (Berenstein et al.,
2012; Friedman et al., 1991).

The genetics of VOGM
Despite significant improvements in the clinical treatment of VOGM, the genetic and
molecular etiology of VOGM is relatively unknown. The only genes associated with
VOGM are in the context of other syndromes. There are seven RASA1 (p120-RasGAP)
mutations in the context of Capillary Malformation – Arteriovenous malformation (CMAVM, OMIM#608354) (Heuchan et al., 2013; Revencu et al., 2008), and one activin A
receptor type II-like 1 (ACVRL1) mutation (Chida et al., 2013) and one Endoglin (ENG)
mutation(Tsutsumi et al., 2011) in the context of Hereditary Hemorrhagic Teleangiectasia
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(HHT, OMIM #187300). A list of all mutations associated with VOGM prior to this work
can be found in Table 1.

RASA1 encodes Ras GTPase-activating protein 1, which inhibits the activity of the RAS
cyclic AMP pathway (Scheffzek et al., 1996; Trahey et al., 1988; Tsygankova et al., 2000)
RASA1 is ubiquitously expressed with particularly high levels in the brain and other
ectoderm-derived tissues (Mollat et al., 1994). Activation of RASA1 improves the GTPase
activity of RAS, changing active RAS-GTP to inactive RAS-GDP. RAS1 plays a crucial
role in the balance of RAS-GTP : RAS-GDP and an impaired RASA1 would lead to a
persistent active, GTP bound RAS configuration and a constitutive RAS activation (Sung
et al., 2016; Vigil et al., 2010).

Rasa1 knockout mice exhibit developmental arrest by E9.25 and death by E10.5
(Henkemeyer et al., 1995). Examination of the Rasa1 knockout mice revealed aberrant
yolk sac angioarchitecture, reduced caliber of the dorsal aorta, and sprouting of aberrant
ventral dorsal aortic branches suggesting delayed primitive endothelial cell reorganization
and eventual embryonic lethality (Henkemeyer et al., 1995). However, heterozygous Rasa1
mice did not demonstrate any vascular phenotypes.

Mutations in RASA1 have been associated with CM-AVM (Boon et al., 2005; Revencu et
al., 2008) which presents with phenotypic heterogeneity. Revencu and colleagues reported
findings on 314 individuals across 132 kindreds with RASA1 mutations and CM-AVM
syndrome (Revencu et al., 2013). This work revealed that 97% of affected individuals
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demonstrated cutaneous manifestations while only 23% presented with a non-cutaneous
AVM, of which 42.6% occurred within the CNS and only 3 were true VOGMs (Revencu
et al., 2013). Another group led by Heuchan (Heuchan et al., 2013), having noted the
connection between VOGM and RASA1 mutations, sequenced RASA1 in 11 individuals
with VOGM. Four of the 11 carried mutations in RASA1. Eight different mutations in
RASA1 have been reported in associating with VOGM (Table 1).

Patients with HHT similarly have phenotypic variability, with some having
teleangiectasias on the skin and mucosa, and AVMs in the lungs, liver, and CNS. One study
revealed that only 3.7% of patients with HHT demonstrate a CNS vascular lesion with only
Dural AV fistulas, cavernous malformations, and parenchymal AVMs described in the
cohort of 321 patients (Maher et al., 2001). The two genes most commonly associated with
HHT are ENG and ACVRL1 (ALK1) which have been associated with HHT types 1 (OMIM
no. 187300) and 2 (OMIM no. 600376), respectively (Abdalla et al., 2000; BayrakToydemir et al., 2006; McAllister et al., 1994). There are several cases of VOGMs in
patients with diagnosed HHT or with a positive family history (Revencu et al., 2013;
Tsutsumi et al., 2011). One report by Tsutsumi and colleagues (Tsutsumi et al., 2011)
demonstrated that a mother with clinical HHT gave birth to a child with a choroidal VOGM
with a mutation identified in the ENG gene (p.Gln558fs). Another report revealed a patient
with subarachnoid hemorrhage secondary to VOGM underlain by a mutation in ACVRL1
(p.Arg218Trp) which was also carried by the sister and mother (Chida et al., 2013).
However, it is unclear if this was a true VOGM or a VGAD due to the lack of imaging.
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Functional expression
With the use of whole exome sequencing, and the increasing prevalence of whole genome
sequencing, more and more data are generated in the search of causes for genetic disease.
Despite technological advances, sequencing itself does not result in a clear genetic
diagnosis or causal gene (Neveling et al., 2013). Even when large cohorts allow for whole
exome-wide significant findings, studies must be made to investigate mechanism of action
to reveal possible avenues of intervention. The need for validation will only increase as
whole exome sequencing becomes more common place with new initiatives such as the
NIH’s Newborn Sequencing in Genomic Medicine and Public Health.

To this end, we have elected to use Xenopus tropicalis, an established model for genetics
research, to screen candidate genes. Unlike Danio rerio (zebrafish) or Xenopus laevis, X.
tropicalis is diploid, which makes it well suited for loss of function studies via gene
depletion. Xenopus is closer to Homo sapiens compared to zebrafish (Ureta-Vidal et al.,
2003). Xenopus is the closest vertebrate model to humans that has the advantages of speed
and lower cost compared to zebrafish and mouse. X. tropicalis grow quickly and reach
sexual maturity faster than X. laevis (Hirsch et al., 2002) and live and reproduce for more
than a decade when cared for properly (Tinsley and Kobel, 1996). Both Xenopus tropicalis
and Xenopus laevis lay thousands of embryos that can easily be manipulated with
microinjection with mRNA for gain of function studies, or with morpholino or
CRISPR/Cas9 for loss of function studies.
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Recent work has shown that F0 CRISPR/Cas9 is highly efficient and can cause biallelic
gene modification in as little as two hours after injection and well before the onset of
zygotic gene expression, with subsequent phenotype detection within 3 days at $35 cost
(Bhattacharya et al., 2015). CRISPR/Cas9 has been shown to be more specific and to have
fewer off-target effects than morpholinos (Gentsch et al., 2018).

Xenopus makes an ideal system for the study of the developing vasculature. Embryos
develop externally and are transparent allowing direct visualization of the heart and tail
vessels. Previous studies have generated a fate map of future vasculature of a 32-cell
embryo (Mills et al., 1999), which allows directed targeting of specific vasculature.
Additionally, much work has gone into the development of the heart, dorsal aorta,
intersegmental vessels, including the signaling between endothelial cells, hematopoietic
cells, and surround tissues have been extensively studied. The available tools for Xenopus
have increased over time including in-situ markers, direct visualization, and transgenic
animals.

The APJ receptor, also known as msr, is a in situ hybridization marker both for
vasculogenesis (development of the heart, posterior cardinal veins, dorsal aorta, viteline
vein network), as well as for angiogenesis of the intersegmental vessels and tail veins (Cox
et al., 2006; Devic et al., 1996). Msr has been the marker of choice in assessing the effect
of drugs on vascular development (Cha et al., 2012; Kalin et al., 2009). Xenopus embryos
are transparent, which allows direct visualization of blood vessels, especially in the tail
which is thin; however, direct visualization remains difficult in other regions and organs
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particularly in the brain. The creation of Xflk-1:GFP transgenic X. laevis (Doherty et al.,
2007) with flk1 being a marker on endothelial cells, and its replication in X. tropicalis, has
allowed direct visualization not only of patent vessels but the stages of angiogenesis from
endothelial cell migration and sprouting to lumenization. This has greatly improved the
ability to perform live imaging and study vasculogenesis and angiogenesis in vivo.

In summary, VOGM will likely become an even more common manifestation of vascular
disease due to the growing population of successfully treated patients. Patients and their
families will continue to ask the questions “Why did I (or my family member) have a Vein
of Galen Malformation?” and “How will this impact my own children in the future?” These
questions must be met, not only for VOGM patients and their families, but for the potential
insights into other AVMs and novel therapeutic targets. Whole exome sequencing lends
itself to an unbiased approach of gene discovery. Any potential genetic findings will
require functional testing to elucidate the mechanism of this disease.
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Figure 1. Representative images of VOGMs.
Lateral representative projections of digital subtraction angiography vertebral artery
contrast injections depicting choroidal VOGM (A) and mural VOGM (B). 3-T time-offlight MR angiography 3D renderings depicting choroidal VOGM (C) and mural VOGM
(D). Fetal T2-weighted MR images depicting a dilated vein of Markowski in a patient with
VOGM, axial projection (E) and sagittal projection (F).
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Table 1. VOGM-associated genetic variants
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V. Statement of Purpose
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The Vein of Galen Malformation (VOGM) is a specific type of arteriovenous malformation
(AVM) that starts in embryonic development weeks 6-11 (Raybaud et al., 1989). Patients
have variable clinical presentations from devastating congestive heart failure at birth to
headaches in young adults (Amacher and Shillito, 1973). The advent of endovascular
treatment greatly decreased mortality from 100-80% down to 15% (Khullar et al., 2010).
However, the multiple staged endovascular surgeries and follow up are costly and the lack
of understanding of the genetic and molecular etiology of VOGM hinder the development
of novel therapies that may prevent VOGM or at the very least the more devastating
neonatal presentations. Only 10 mutations distributed amongst three genes have been
associated with VOGM. There are seven RASA1 (p120-RasGAP) mutations in the context
of Capillary Malformation – Arteriovenous malformation (CM-AVM, OMIM#608354)
(Heuchan et al., 2013; Revencu et al., 2008), and one activin A receptor type II-like 1
(ACVRL1) mutation (Chida et al., 2013) and one Endoglin (ENG) mutation (Tsutsumi et
al., 2011) in the context of Hereditary Hemorrhagic Teleangiectasia (HHT, OMIM
#187300). Uncovering the genetics of VOGM would provide a better understanding of
VOGM, AVMs, and neurovascular development. The overall aim of this project is to
investigate the developmental regulation of vasculogenesis and angiogenesis with regards
to arteriovenous malformations. In order to accomplish this goal, we propose the following
aims:

Specific Aim 1: Establishing a large and precisely phenotyped VOGM patient cohort
In this aim we will establish a VOGM patient cohort with an innovative and collaborative
social media recruitment platform. Probands that satisfy our inclusion criteria,
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demonstrate: 1) a true VOGM, with an ectatic fistula feeding into the median
prosencephalic vein and not a VGAD; 2) the availability of both biological parents to
contribute DNA; are actively recruited from Yale School of Medicine and our collaborating
institutions (Boston Children’s Hospital, USA). We will also employ a social media
recruitment strategy utilizing Facebook, approved by the Yale University IRB/HIC
(Kristopher Kahle, PI; HIC/HSC Protocol#: 1602017144), which allows us to efficiently
identify and rapidly obtain DNA from VOGM patients around the world using mailed
consent forms and buccal swab kits. This process has been employed both by our group
and others to significant effect in studying genetic disease (Furey et al., 2018; Timberlake
et al., 2016). We place emphasis on collecting DNA from all nuclear family members due
our hypothesis of phenotypic variability. For each index case, we obtain full medical
records, prior clinical genetic testing, and importantly, any full brain CT-angiogram, MRangiogram, traditional angiogram, and neuroradiology reports.

Specific Aim 2: Identification of novel VOGM-causing genes using whole exome
capture and massively parallel DNA sequencing. In this aim we will utilize WES and
bioinformatics to identify novel VOGM-causing mutations. All trios are sequenced at the
Yale Center for Genomic Analysis (YCGA). Resulting sequence is analyzed with
computational pipelines that enable the rapid identification of rare/novel/de novo variants
which are predicted to alter the function of the encoded protein, are specific for the disease,
and are not detected in published and internal reference SNV sequence databases of
unaffected patients (Furey et al., 2018). Assuming that there are single loci which account
for VOGM, we predict that we will detect several novel VOGM genes which we predict
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will cluster in pathways related to arterio-venous specification ((Fish and Wythe, 2015)),
the axon guidance and neuro-vascular development pathways (Klagsbrun and Eichmann,
2005), or in pathways related to RASA1, ENG, and ACVRL1. We anticipate it will be
possible to identify multiple independent mutations in the same genes or genetic pathways
in different individuals with similar phenotypes.

Specific Aim 3. Functional assessment of discovered VOGM genes using CRISPR
gene editing in Xenopus tropicalis. In this aim, we plan to develop a novel method of
functionally validating candidate mutations that utilizes CRISPR gene editing in Xenopus
tropicalis coupled with in situ hybridization, quantitative Optical Coherence Tomography
(qOCT), and confocal imaging of the brain to assess the functional impact of discovered
VOGM-causing mutations in vivo. To do this, we will employ F0 CRISPR gene editing in
Xenopus tropicalis, a rapid, diploid amphibian system (Bhattacharya et al., 2015), to
examine vasculogenesis, angiogenesis, and brain vasculature. F0 CRISPR/Cas9 is highly
efficient and can cause biallelic gene modification in as little as two hours after injection
and well before the onset of zygotic gene expression, with subsequent phenotype detection
within 3 days at $35 cost (Bhattacharya et al., 2015). To phenotype embryos, we will
employ in situ hybridization of vessel marker msr at the time of vasculogenesis and early
angiogenesis (Devic et al., 1996), and examine the brain vasculature in vivo using
transgenic Xflk1:GFP ((Doherty et al., 2007) to examine the vasculature throughout the
animal as well as in the brain at the evolutionary precursor of the median prosencephalic
vein. This work will help establish Xenopus as a means of studying brain vasculature, will
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provide insight into the mechanism of VOGM and guide future investigations and
mechanisms for therapeutic strategies.
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VI. Mutations in chromatin modifier and Ephrin signaling genes in Vein of Galen
Malformation
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VI. Mutations in chromatin modifier and Ephrin signaling genes in Vein of Galen
Malformation
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INTRODUCTION

Embryogenesis requires vascular development to meet hemodynamic and nutritive
demands. Arterio-venous (A-V) specification in model organisms is geneticallydetermined and results in the differential expression of genes in arteries and veins prior to
establishment of circulation (Fish and Wythe, 2015). For example, during development
Ephrin-B2 and its receptor Eph-B4 are exclusively expressed in arteries or veins,
respectively (Adams et al., 1999; Gerety et al., 1999; Wang et al., 1998). Murine deletion
of Efnb2 or EphB4 impairs A-V specification and causes arterio-venous malformations
(AVMs), high-flow vascular lesions characterized by direct connections of arteries to veins
without intervening capillaries. A-V specification requires orchestrated activity of multiple
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signaling cascades (e.g., Eph-Ephrin, Hedgehog, VEGF, TGF-beta, and Notch) and
transcriptional networks (e.g., HEY and HES, SOX factors, and COUP-TFII) (Fish and
Wythe, 2015). Nonetheless, the genetic determinants of A-V specification in humans
remain incompletely understood.

During normal brain development, primitive choroidal and subependymal arteries that
perfuse deep brain structures are connected via an intervening capillary network to the
embryonic precursor of the Vein of Galen (i.e., the median prosencephalic vein of
Markowski [MPV]). The MPV returns deep cerebral venous blood to dural sinuses that
drain into the internal jugular veins (Raybaud et al., 1989). Vein of Galen malformations
(VOGMs), the most common and severe neontal brain AVMs (Deloison et al., 2012; Long
et al., 1974), directly connect primitive choroidal or subependymal cerebral arteries to the
MPV, exposing it to dangerously high blood flow and pressures that can result in highoutput cardiac failure, hydrocephalus, and/or brain hemorrhage (Recinos et al., 2012).
VOGMs are also often associated neurodevelopmental delay and congenital heart defects
(CHDs) (McElhinney et al., 1998). While endovascular partial obliteration of anomalous
A-V connections has improved VOGM outcomes (Altschul et al., 2014; Mitchell et al.,
2001), many VOGMs remain refractory to intervention, which are also are inaccessible to
many patients.

Limited knowledge of the molecular pathophysiology of VOGMs has hindered
development of early diagnostic and targeted therapeutic strategies. Considered isolated,
sporadic congenital lesions, rare VOGMs have been associated with Mendelian disorders,
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including 8 cases of autosomal dominant (AD) capillary malformation-arteriovenous
malformation (CM-AVM) syndrome type 1 (CM-AVM1) caused by RASA1 mutation
(OMIM# 608354) (Duran et al., 2018a; Revencu et al., 2013); 2 cases of AD CM-AVM
syndrome type 2 (CM-AVM2) caused by EPHB4 mutation (Amyere et al., 2017), and
single cases of AD Hereditary Hemorrhagic Telangiectasia (HHT) type 1 (HHT1) due to
ENG mutation (OMIM# 187300) (Tsutsumi et al., 2011) and AD HHT type 2 (HHT2)
caused by ACVRL1 mutation (OMIM# 600376; 1 case) (Chida et al., 2013).

Traditional genetic approaches have been limited in their ability to identify additional
causative genes for VOGM because cases are rare and most often sporadic (Xu et al., 2010).
This limitation motivates application of whole-exome sequencing (WES) to large numbers
of affected subjects and their families, searching for genes mutated in probands more often
than expected by chance. This unbiased approach has aided the study of other genetically
heterogeneous neurodevelopmental disorders (de Ligt et al., 2012; Epi et al., 2013; Iossifov
et al., 2014; Iossifov et al., 2012; Krumm et al., 2015; Neale et al., 2012; O'Roak et al.,
2011; O'Roak et al., 2012; Rauch et al., 2012; Sanders et al., 2012; Timberlake et al., 2016;
Timberlake et al., 2017; Vissers et al., 2010; Willsey et al., 2017), including those
associated with brain malformations (Barak et al., 2011; Bilguvar et al., 2010; MishraGorur et al., 2014; Nikolaev et al., 2018), CHDs (Homsy et al., 2015; Jin et al., 2017; Zaidi
et al., 2013), and congenital hydrocephalus (Furey et al., 2018). We hypothesized that
VOGMs might arise from damaging de novo mutation events or incomplete penetrance of
rare transmitted variants.
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RESULTS

VOGM cohort characteristics and whole exome sequencing
We recruited 55 probands with radiographically confirmed VOGMs (see STAR Methods)
treated by endovascular therapy, including 52 parent-offspring trios with a single affected
offspring and 3 singleton cases. 62% of probands were diagnosed prenatally or within one
month after birth; only one was diagnosed after age 2. Common features at diagnosis
included high output cardiac failure (62%), macrocephaly (64%), hydrocephalus (60%),
and prominent face/scalp vasculature (49%). Among the CHDs found in 9% were partial
anomalous pulmonary venous return, patent ductus arteriosus, and pulmonary valve
stenosis. Supplementary Table 1 summarizes cohort demographics, clinical features, and
radiographic classification, including angio-architectural subgroups (Lasjaunias et al.,
2006). 37 of the 55 patients in our cohort presented with “choroidal” type lesions, defined
as VOGMs with numerous feeder vessels and “pseudoniduses” that communicate with the
MPV (Lasjaunias et al., 2006). The remaining 18 probands presented with “mural”
VOGMs, characterized by fewer vessels of larger caliber that fistulize into the MPV
(Lasjaunias et al., 2006). See Supplementary Figure 1 for representative VOGM images.

DNA was isolated and WES performed as described (Timberlake et al., 2016). WES from
1,789 control trios comprising parents and unaffected siblings of autism probands were
analyzed (Fischbach and Lord, 2010; Krumm et al., 2015) by our in-house informatics
pipeline. In both cases and controls, ³ 94.6% of targeted bases had > 8 independent reads
and ³ 89.8% had > 15 independent reads. (See Supplementary Table 2 for exome
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metrics). Variant calling was by Genome Analysis Toolkit (GATK) HaplotypeCaller
(McKenna et al., 2010; Van der Auwera et al., 2013), and allele frequency annotation by
the Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database
(gnomAD) (Lek et al., 2016) (see STAR Methods). De novo mutation identification was
by TrioDeNovo (Wei et al., 2015). MetaSVM was used to infer the impact of missense
mutations (Dong et al., 2015). Missense variants were considered damaging if predicted
deleterious by MetaSVM (D-mis). Inferred loss-of-function (LoF) mutations, including
stop-gains, stop-losses, frameshift insertions/deletions, and canonical splice site mutations
were also considered damaging. Mutations in genes of interest were validated by PCR
amplification and Sanger sequencing (Supplementary Figure 2).

Enrichment in damaging de novo mutations in VOGM probands
The de novo mutation rate in probands was 1.56 × 10-8 per base pair, with 1.21 de novo
coding region mutations per proband (Supplementary Table 3), consistent with
expectation and prior results (Homsy et al., 2015; Timberlake et al., 2017; Ware et al.,
2015).

Total de novo mutation burden in controls was also as previously reported

(Timberlake et al., 2017). The distribution of types of de novo coding mutations in
probands was compared to that expected from the probability of mutation of each base in
the coding region and flanking splice sites (Samocha et al., 2014). While synonymous
mutations and inferred tolerated missense (T-mis) mutations in probands were not
significantly enriched, de novo D-mis mutations in probands were marginally enriched (P
= 0.01; enrichment = 2.05-fold; Supplementary Table 3). In contrast, control subjects
displayed no enrichment in any class of coding region mutation (Supplementary Table
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3). The observed excess of damaging de novo mutations in probands over that expected
predicts these mutations contribute to ~13% of VOGM cases.

One gene, KEL, exhibited more than one protein-altering de novo mutation (Figure 1).
Among the 52 trios analyzed, we observed a near-significant enrichment of protein-altering
de novo mutations in KEL (one-tailed Poisson test P = 4.2 x 10-6; Benjamini-Hochberg
false discovery rate [BH-FDR] = 0.08). One of these mutations caused premature
termination (p.Gln321*) and the other was a missense mutation p.Gly202Ser (CADD =
22.6), both impacting the KELL polypeptide’s peptidase domain (Figure 1).

We analyzed the burden of de novo mutations in genes highly intolerant to heterozygous
LoF mutation (LoF-intolerant genes; pLI ≥ 0.9) (Lek et al., 2016), consistent with loss of
one gene copy markedly impairing reproductive fitness. de novo D-mis mutations were
marginally enriched (6 mutations; P = 0.02; enrichment = 2.82-fold; Table 1), of which
four (3 D-mis and the only LoF mutation) occurred in genes encoding chromatin modifiers
(KMT2D, SMARCA2, SIRT1, and KAT6A) (Figure 2). The 547 genes in the chromatin
modifier gene ontology term GO:0016569 include 272 LoF-intolerant chromatin modifier
genes; mutations in this set are enriched (P = 8.9 x 10-4; enrichment = 9.63-fold; Table 1),
but de novo mutations in the LoF-intolerant chromatin modifier gene set were not enriched
in controls (Table 1). A case-control analysis using the two-tailed binomial exact test
(Sanders et al., 2012; Willsey et al., 2017) further supported this result (Supplementary
Table 4). In an orthogonal analysis of all genes using the permutation-based test (1 million
iterations), the probability of finding 4 or more damaging de novo mutations in LoF-
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intolerant chromatin modifiers among a total of only 19 damaging de novo mutations in all
genes was also low (empirical P = 3.5 x 10-3; expected number = 0.66; see STAR
Methods). Damaging de novo mutations in chromatin modifiers were thus identified in
~7% of all VOGM probands (Supplementary Table 5). Missense mutations occur in key
functional domains of the encoded proteins at positions conserved through worm (KAT6A
and KMT2D) and yeast (SMARCA2) (Figure 2, panel C; Supplementary Table 5).
Clinical characteristics of probands harboring these mutations are shown in Figure 2 and
Supplementary Table 5.

Enrichment of rare damaging transmitted mutations in EPHB4
We next assessed the total burden in all probands of rare (minor allele frequency [MAF] ≤
2 x 10-5) de novo and transmitted D-mis and LoF mutations in LoF-intolerant genes (see
STAR Methods). The probability of the observed number of rare variants in each gene
occurring by chance was calculated by comparing observed to the expected burden,
adjusting for gene lengths (Besse et al., 2017). Analysis of damaging variants in LoFintolerant genes revealed genome-wide significant enrichment (Bonferroni multiple testing
threshold = 2.63 x 10-6) of mutations only in EPHB4 (pLI = 0.99), with one LoF and three
independent D-mis mutations (one-tailed binomial P = 7.47 x 10-10; BH-FDR = 2.40 x 106

; enrichment = 341.13-fold; Figure 3, panel A; Table 2).

Independent case-control gene burden analyses for damaging variants in all probands
versus a cohort of 3,578 autism parental and ExAC controls showed a significant mutation
burden in EPHB4 vs. autism parental controls (one-tailed Fisher’s P = 1.68 x 10-6, odds
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ratio = 89.97, 95% CI [19.29, Inf]) and vs. ExAC controls (one-tailed Fisher’s P = 1.98 x
10-6, odds ratio = 49.76, 95% CI [16.39, Inf]); Supplementary Table 6). The Bonferronicorrected threshold for the 3,230 LoF-intolerant genes, 1.55 x 10-5, was also surpassed by
the CAD gene (one-tailed binomial P = 4.17 x 10-6; BH-FDR = 0.01; enrichment = 101.08fold).

All EPHB4 mutations were transmitted; three of these have allele frequencies of zero in
ExAC and gnomAD, while one has a MAF of 1.13 x 10-5 in gnomAD. All D-mis mutations
in EPHB4 alter highly conserved amino acid residues (Figure 4, panel C; Table 2).
Mutations p.Lys650Asn and p.Phe867Leu lie in the tyrosine kinase domain of the veinspecific (Gerety et al., 1999) Eph-B4 receptor. p.Ala509Gly lies in one of two EphB4
extracellular fibronectin III domains believed to bind extracellular matrix (Figure 4, panel
C).

7 additional family members without diagnosed VOGM in these kindreds carried the same
mutations. However, three EPHB4 mutation carriers exhibited uncommon cutaneous
vascular lesions. Thus in kindred VGAM-115, the mutation-carrying father had an
abdominal port wine stain, and the proband’s mutation carrier sibling had atypical left
cheek and posterior thigh capillary malformations (Supplementary figure 3, panels A &
B). Similarly, the mutation-carrying mother in kindred KVGAM-33 had an atypical
capillary malformation on her left arm, while the proband’s mutation carrier sibling had an
atrial septal defect (Figure 4, panel B). Vascular and cardiac abnormalities were absent
among non-mutation carriers in these families. All VOGMs associated with EPHB4
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mutations were of the choroidal subtype (Figure 4, panels A & B). Together, these
findings provide evidence of incomplete penetrance and variable expressivity of EPHB4
mutations. Interestingly, 2 of 54 CM-AVM2 patients with EPHB4 mutations also had
VOGM (Amyere et al., 2017).

Wild type and VOGM-mutant Eph-B4 (p.Ala509Gly; p.Lys650Asn; p.Phe867Leu) were
expressed in mammalian cells (see STAR Methods), and levels of Eph-B4 tyrosine (Tyr)phosphorylation, an index of tyrosine kinase activity (Ferguson et al., 2015; Lisabeth et al.,
2013), were compared. Eph-B4 kinase domain mutants p.Lys650Asn and p.Phe867Leu
showed reduced or absent phosphorylation, respectively (Figure 4, panel D). In contrast,
the extracellular fibronectin III domain mutant p.Ala509Gly showed unchanged
phosphorylation.

Eph-B4 Tyr phosphorylation creates docking sites for signaling molecules via a
phosphotyrosine-SH2 domain interaction, facilitating Eph-B4 downstream signaling
(Pawson and Scott, 1997; Wang et al., 2002). RASA1-encoded Ras GTPase-activating
protein 1 (Ras-GAP) binds to these docking sites and regulates downstream signaling
pathways (Kawasaki et al., 2014; Roth Flach et al., 2016). We immunoprecipitated wild
type or VOGM-mutant Eph-B4 from mammalian cells co-expressing Ras-GAP. Ras-GAP
co-immunoprecipation with EPHB4 mutant p.Lys650Asn was reduced, and Ras-GAP
failed to bind Eph-B4 mutant p.Phe867Leu (Figure 4, panel E). In contrast, wild type
Eph-B4 and Eph-B4 p.Ala509Gly bound Ras-GAP with similar affinity. These results are
consistent with the cytoplasmic mutations impairing receptor kinase activity. The
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extracellular mutation alters the fibronectin domains, likely to affect signaling by altering
binding to extracellular matrix ligands (a hypothesis not yet tested).

Recurrent rare damaging transmitted mutations in CLDN14
Expansion of the analysis to include the burden of rare (MAF ≤ 2 x 10-5) D-mis and LoF
mutations in all genes identified one additional gene, CLDN14, with genome-wide
significant damaging mutation burden (one-tailed binomial P = 6.44 x 10-7; BH-FDR =
0.01; enrichment = 190-fold; Figure 3, panel B; Table 2). Comparing CLDN14 mutation
burden by case-control analysis against both autism parental controls (odds ratio = Inf, 95%
CI [38.42, Inf]; one-tailed Fisher’s P = 3.38 x 10-6; Supplementary Table 6a) and ExAC
controls, odds ratio = 67.82, 95% CI [17.66, Inf]; one-tailed Fisher’s P = 1.65 x 10-5;
Supplementary Table 6b) supported the significance of this finding. The three rare
damaging CLDN14 mutations were all heterozygous transmitted missense mutations (5.5%
of probands; Figure 5). Two are identical (p.Val143Met) and present in unrelated VOGM
probands, with MAF of 0 in Non-Finnish Europeans in ExAC. Beagle v3.3.2 kinship
analysis (Browning and Browning, 2011; Stuart et al., 2015) and trio analysis using 139
phased genotypes flanking the mutation revealed that p.Val143Met variant lies on a
segment shared identically by-descent from a common ancestor by the two probands, with
a minimum shared segment of 0.34 Mb. Nonetheless, these probands shared no other rare
variants, indicating that they do not share a recent common ancestor. The other rare
damaging variant, p.Ala113Pro, is absent in ExAC, with MAF 8.28 x 10-6 in gnomAD.
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CLDN14 encodes Claudin-14, a tight junction protein expressed in epithelia and
endothelial cells of brain and kidney (Kniesel and Wolburg, 2000; Wattenhofer et al.,
2005). Claudin extracellular loops make homo- or heterotypic interactions with adjacent
cells to form the tight junction barrier (Van Itallie and Anderson, 2013). p.Val143Met alters
a highly conserved residue in the second extracellular loop of Claudin-14, and is predicted
to be deleterious by MetaSVM, CADD, Polyphen2, and SIFT. p.Ala113Pro lies in the
second intracellular loop of Claudin-14(Figure 5, panel C; Supplementary Figure 4).

Interestingly, in one of the families (KVGAM20) harboring the recurrent Claudin-14
mutation p.Val143Met, cutaneous vascular lesions segregated with the mutation among
family members. The mother who transmitted the mutation had a port wine stain on her
left thigh, while her children (proband and carrier sibling) had similar atypical capillary
malformations in the nuchal area. This VOGM proband also had a midline atypical
capillary malformation on her lower back (Supplementary Figure 3, panels G-J).

Enrichment of mutations in genes in the Ephrin signaling pathway
To search for pathways enriched for rare damaging mutations in VOGM, LoF-intolerant
genes harboring damaging de novo and/or rare (MAF ≤ 2 x 10-5) damaging transmitted
mutations, along with KEL and CLDN14, were input into Ingenuity Pathway Analysis
(IPA; May 2018 version; total 128 input genes) (Kramer et al., 2014). Axonal guidance
signaling, essential for vascular patterning and regulated by Ephrin-Eph receptor signaling
(Adams and Eichmann, 2010), was the most significantly enriched canonical pathway (P
= 6.61 x 10-8; BH-FDR = 1.33 x 10-5), including Ephrin receptor signaling pathway genes
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(also significant). Nine additional IPA pathways were significant after B-H correction
(Supplementary Table 7). Because IPA does not adjust for gene length, we tested each of
these pathways in the case-control analysis (see STAR Methods) using ethnicity-matched
autism parents and ExAC controls. Axonal guidance and Ephrin receptor signaling
pathways showed significant enrichment in cases (Supplementary Tables 8).

We further analyzed mutation burden in genes in these two pathways by binomial test,
comparing observed to expected values as corrected for gene size (see STAR Methods).
Significant enrichment in both axonal guidance and Ephrin receptor signaling pathways
was observed in cases, whereas analyses of synonymous variants in cases as well as rare
damaging variants in autism parents and ExAC controls showed no significant enrichment
(Supplementary Tables 9). Lastly, we found that most of the signal in the axonal guidance
pathway was attributable to the Ephrin receptor signaling pathway because, after removal
from analysis of the latter genes, the axonal guidance pathway was no longer significantly
enriched (Supplementary Table 10). Detailed variant information of damaging mutations
in genes that contributed to the significant result is described in Supplementary Table 11.

Of note, EFNB2 (pLI = 0.94), encoding the Eph-B4 ligand Ephrin-B2, harbored the rare
D-mis mutation p.Arg277His in a neonate with a choroidal VOGM (Supplementary
Figure 5). EFNB2 is represented in the IPA axonal guidance and Ephrin receptor signaling
gene sets, but this specific EFNB2 variant was not included as input in our pathway analysis
because its MAF slightly exceeded our threshold of 2 x 10-5 (MAF of 1.88 x 10-5 and 2.89
x 10-5 in ExAC and gnomAD, respectively). The proband’s EFNB2 mutation-carrying
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mother, while not having VOGM, exhibited multiple atypical nuchal capillary
malformations. Of note, Ephrin-b2 knockout mice phenocopy eph-b4 knockout mice,
exhibiting CNS and systemic AVMs, defects in cerebral angiogenesis, and embryonic
lethality (Wang et al., 2010b).

Rare damaging mutations in genes implicated in Mendelian AVM syndromes
VOGM is a rare feature in patients with CM-AVM types 1 and 2 due to mutation in RASA1
(Duran et al., 2018a; Revencu et al., 2013) and EPHB4 (Amyere et al., 2017), respectively.
VOGM has also previously been associated with single cases of Hereditary Hemorrhagic
Telangiectasia (HHT) type 1 due to ENG mutation (Tsutsumi et al., 2011) and HHT type
2 due to ACVRL1 mutation (OMIM# 600376) (Chida et al., 2013).

Our VOGM cohort included no ENG mutations. We found one damaging mutation in
RASA1 (p.Arg709*, Supplementary Table 11), encoding the Eph-B4 binding partner and
effector Ras GTPase-activating protein 1 (Ras-GAP) (Kawasaki et al., 2014), in a patient
with a mural VOGM. This patient and mutation has been previously reported (Revencu et
al., 2013)and was independently ascertained in the present study.

A single patient with a choroidal VOGM had a damaging p.Arg484Gln mutation in
ACVRL1 (Supplementary Table 12), encoding ALK1, a receptor kinase in the TGF-β
signaling pathway highly expressed in developing human vasculature (Zhang et al., 2017).
This mutation altering a conserved residue in the ALK1 kinase domain was reported in
HHT2 with isolated pulmonary hypertension (ClinVar accession RCV000198604.1;
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rs863223408) (Harrison et al., 2005). However, neither the ACVRL1-mutant VOGM
proband nor family members carrying the mutation exhibited HHT-associated findings
(e.g., epistaxis or telangiectasia) or other vascular abnormalities. ACVRL1 (ALK1) is a
known regulator of Ephrin-B2-Eph-B4 signaling (Kim et al., 2012; Roman and Hinck,
2017; Zhang, 2009), and acvrl1 deficient mice exhibit markedly enlarged cerebral vessels
with arteriovenous shunting and altered Eph-B4 expression (Walker et al., 2011).

Unrelated probands with mural VOGMs carried two rare damaging mutations (p.Gly39Ser
and p.Asn373Ser) in the ACVRL1 paralog, ACVR1 (pLI = 0.96); Supplementary Table
12; Supplementary Figure 6, panels A & B), a gene not previously implicated in VOGM.
The ACVR1 p.Asn373Ser VOGM proband also had an atrial septal defect and partial
anomalous pulmonary venous return (Supplementary Figure 6, panel B), and two
mutation carriers in the family had cutaneous capillary malformations (Supplementary
Figure 6, panel B). Neither the proband nor other family members had common HHT
features (Abdalla et al., 2003). ACVR1 encodes the receptor serine-threonine receptor
kinase ALK2 coordinating with TGF-beta type 2 receptors and co-receptors such as
Endoglin (ENG) (Barbara et al., 1999; Chen et al., 1998; Wolfe and Myers, 2010).
p.Gly39Ser alters a conserved residue in the extracellular ligand binding domain
(Supplementary Figure 6, panel C). p.Asn373Ser alters a conserved residue predicted to
be structurally critical to the cytoplasmic serine-threonine kinase (Supplementary Figure
6, panels D & E).
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DISCUSSION

The rarity and the sporadic nature of VOGM have hindered its genetic understanding. This
study, the largest trio-based genomic analysis of VOGM to date, has provided the following
novel insights. First, probands exhibit an excess of damaging de novo mutations (~13% of
cases); among these, mutations in chromatin modifier genes with essential roles in brain
and heart development are enriched, and inferred to impact ~8% of cases. Second, there is
a prevalence of rare inherited damaging mutations in the Ephrin signaling genes, including
a genome-wide significant burden in EPHB4, (another ~16% of probands). Third, inherited
mutations show incomplete penetrance and variable expressivity, with mutation carriers
often exhibiting cutaneous vascular lesions, suggesting a two-hit mechanism. Thus, while
rare mutations of large effect contribute to a significant fraction of VOGM cases, mutations
in many additional genes likely contribute to disease pathogenesis. Our results support this
hypothesis, suggesting potential pathogenic roles for de novo KEL mutations and rare,
inherited CLDN14 mutations. However, the small number of observations and lack of
replication studies require validation and extension by larger follow-up studies. Of note,
analysis of rare homozygous and compound heterozygous genotypes (MAF ≤ 0.001)
revealed no genes with more than one such genotype. See Supplementary Table 13 for
proband information and identified likely pathogenic mutations.

Genes encoding covalent histone modifiers and chromatin remodelers have been
implicated in autism (De Rubeis et al., 2014), CHD (Jin et al., 2017), congenital
hydrocephalus (Furey et al., 2018), and other congenital disorders (Feinberg, 2018). In our
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cohort, 4/55 probands had de novo mutations in chromatin modifiers. Enrichment of these
mutations in our cohort and the conservation of the mutated residues in critical domains of
protein function are consistent with each of these mutations contributing to VOGM
pathogenesis. All four genes (KMT2D, SMARCA2, SIRT1, KAT6A) are highly expressed in
the developing human and murine brain (Machida et al., 2001; Ogawa et al., 2011; Pollen
et al., 2015; Tham et al., 2015) and essential for neuronal and/or vascular development
(Griffin et al., 2008; Potente et al., 2007; Van Laarhoven et al., 2015). SMARCA2, KAT6A,
KMT2D are mutated in Mendelian diseases that feature intellectual disability and/or
epilepsy (Dentici et al., 2015; Morin, 2003). Mendelian phenotypes associated with KAT6A
and KMT2D mutations include vascular defects and CHD (Arboleda et al., 2015; Van
Laarhoven et al., 2015). Multiple mutated chromatin modifiers are shared among patients
with CHD and autism (Homsy et al., 2015; Jin et al., 2017; Zaidi et al., 2013) ~87% of
CHD patients with LoF de novo mutations in chromatin modifier genes exhibit
neurodevelopmental phenotypes (Jin et al., 2017). These observations suggest that
neurodevelopmental phenotypes in VOGM patients currently attributed to secondary CNS
damage may instead reflect primary impairment from genetic mutation.

The role of Eph-B4 in A-V specification is well established in model systems (Mosch et
al., 2010; Zhang and Hughes, 2006). Heterozygous missense variants in EPHB4 have also
been reported in two families with non-immune hydrops fetalis and/or atrial septal defect
(HFASD; OMIM # 617300) (Martin-Almedina et al., 2016) and 54 families with CMAVM2, featuring isolated cutaneous capillary malformations (63%) and associated AVMs
(35%) (Amyere et al., 2017). We found damaging mutations in EPHB4 in 7% of VOGM

40

probands in this cohort. Two of 52 prior CM-AVM2 patients with EPHB4 mutations were
reported to have VOGMs (Amyere et al., 2017). During preparation of this manuscript,
(Vivanti et al., 2018) reported 3 transmitted damaging mutations in EPBH4 among whole
exome sequences from 19 VOGM case-parent trios, and two additional mutations from
targeted sequencing of 32 other singleton VOGM probands. Eph-b4 antisense morpholino
knockdown in zebrafish embryos disrupts angioarchitecture of the dorsal longitudinal vein,
homolog of the human Vein of Galen precursor (Aurboonyawat et al., 2007). We conclude
that heterozygous EPHB4 germline mutations contribute to a spectrum of vascular
pathology, and EPHB4 is a bona fide VOGM risk gene.

Our analysis also demonstrated enrichment of rare heterozygous damaging mutations in
Ephrin signaling genes (Supplementary Table 11). These genes are expressed in the
embryonic human brain and vasculature (Guo et al., 2012), regulate neurovascular
development, and can be mapped into a single experimentally-supported STRING
interactome (Supplementary Figure 7, see STAR Methods). Cutaneous vascular lesions
are a common hallmark of developmental vascular disorders such as RASA1- and EPHB4mutated CM-AVM (Amyere et al., 2017; Revencu et al., 2013); ENG1- and ACVRL1mutated HHT (Chida et al., 2013); and RASA1-mutated Parkes Weber syndrome
(Brouillard and Vikkula, 2007). We found similar cutaneous vascular lesions in VOGM
kindreds harboring mutations in EFNB2, EPHB4, EPHA4, ACVR1, and CLDN14. These
findings further implicate these genes in a Eph-B4-RASA1 signaling network
(Supplementary Figure 8).
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Transmitted VOGM-associated mutations show incomplete penetrance. Moreover, many
of the identified VOGM-associated genes harbouring damaging de novo and inherited
mutations have been implicated in other Mendelian diseases, sometimes producing
different phenotypes. These observations highlight the pleiotropy with variable
expressivity resulting from these mutations. These features have been described in other
diseases. For example, haploinsufficiency for the identical chromatin modifier genes
results in CHD (Zaidi et al., 2013) or autism (Iossifov et al., 2014), or both. Variable
expressivity of VOGM and associated features could arise from environmental modifiers
(Stuart et al., 2015). in concert with the rare mutations identified and/or specific genetic
modifiers (Timberlake et al., 2016). Co-mutation of genes in KVGAM20, VGAM100, and
KVGAM45 could be important in this regard (see Supplementary Table 13). Sequencing
additional exomes from VOGM kindreds will help clarify this issue.

The mechanisms by which syndromes characterized by abnormal A-V specification
present with multifocal distributions of lesions remains poorly understood. Since 68% of
VOGM families with full clinical data had capillary malformations or other uncommon
cutaneous vascular lesions, and that identified mutations in probands were found in all
family members with these cutaneous lesions, provide evidence linking VOGM and the
cutaneous lesions to the same mutations (Supplementary Table 13). This is consistent
with a two-hit mechanism, in which phenotypic expression relies upon an inherited
mutation and a second, post-zygotic mutation in the other wild-type allele (Brouillard et
al., 2002; Pagenstecher et al., 2009). This mechanism has been shown for other hereditary
multifocal vascular malformations such as RASA1-mutated CM-AVM1 (Revencu et al.,

42

2013), glomuvenous malformations (OMIM# 138000), cutaneomucosal venous
malformation (OMIM# 600195), and cerebral cavernous malformations (OMIM# 116860)
(Pagenstecher et al., 2009). In this context, phenotypic expression depends on the cell types
in which somatic mutations occur, and could explain the low penetrance of VOGM arising
from transmitted mutations. Further work, including exome sequencing of lesional VOGM
tissue, will test this hypothesis.

Although the identified de novo KEL mutations and inherited CLDN14 mutations will
require further validation by WES of additional VOGM patients and functional studies,
several observations suggest the importance of the current findings. KEL, encoding the
Kell blood group transmembrane glycoprotein, was the only gene in our study that
harbored more than one protein-altering de novo mutation (see Figure 1). Both the
premature termination and p.Gly202Ser mutations in Kell alter its peptidase domain,
shown to generate vasoactive endothelin peptides via cleavage of the endothelin-3 proprotein (Lee et al., 1999). Endothelins provide vascular-derived axonal guidance cues
(Makita et al., 2008) involved in Ephrin-dependent vascular patterning (Adams and
Eichmann, 2010).

CLDN14 was the only other gene besides EPHB4 with genome-wide significant
enrichment of transmitted damaging mutations. Recessive LoF genotypes in CLDN14
cause sensorineural deafness type 29 (OMIM # 614035); in contrast, VOGM-associated
CLDN14 mutations are heterozygous and D-mis, and include a recurrent missense
mutation, suggesting gain-of-function or neomorphic effects, and phenotypic
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heterogeneity. Claudin-14 is a tight junction protein in brain epithelia and endothelial cells
(Kniesel and Wolburg, 2000; Wattenhofer et al., 2005). The regulation of tight junction
formation by Claudins can impact endothelial cell permeability, integrity, and proliferation
(Gonzalez-Mariscal et al., 2007; Morita et al., 1999). The recurrent VOGM-associated
Claudin-14 mutation in lies in the large 2nd extracellular loop that likely plays a role in tight
junction formation. Endothelial cells heterozygous, but not homozygous, for CLDN14
exhibit disruption of ZO-1-positive cell-cell junctions, abnormal distribution of basement
membrane laminin, increased VEGF-stimulated angiogenesis, and significantly enhanced
cell proliferation – suggesting a gene dosage effect (Baker et al., 2013). Functional
interactions have been reported between Claudins and Ephrin-B2-EphB4 bi-directional
signaling (Tanaka et al., 2005a). In support of a possible Ephrin-Claudin-14 interaction is
the fact that one of the families harboring the recurrent Claudin-14 mutation p.Val143Met
had CM-AVM-like cutaneous vascular lesions that segregated with the mutation in family
members (see Figure 5, panel B). The role of Claudin-14 in potential EphB4-dependent
A-V specification will be a topic of future investigation.

These findings suggest mutation carrier offspring may be at increased risk of VOGMs, as
well as capillary malformations and potentially other AVMs. However, not all mutation
carriers develop capillary malformations, making absence of capillary malformations an
unreliable clinical marker for transmission risk in affected families. These observations
suggest the importance of family history and mutation-based screening for risk assessment.
The narrow developmental window of gestational weeks 6-11 during which PVM fistulas
form (Raybaud et al., 1989) poses a challenge to improved early therapeutic strategies for

44

VOGM. Thus, attempted diagnosis with intention to treat must occur before the safe
gestational age threshold for amniocentesis (Shulman et al., 1994). These difficulties
highlight the need for continued genetic research on VOGM, with focus on mechanistic
implications of recently discovered VOGM-associated mutations.

Eph-B4 kinase domain mutations remove inhibition of downstream RAS/MAPK/ERK1/2
and PI3K/AKT/mTORC1 signaling cascades (Kim et al., 2002; Salaita and Groves, 2010;
Xiao et al., 2012). We showed select VOGM-associated Eph-B4 mutations result in
decreased binding of Eph-B4 to RASA1(see Figure 4, panel E). PI3K/AKT/mTORC1 upregulation has been noted in capillary malformations of RASA1-mutant CM-AVM1
patients (Kawasaki et al., 2014). Therapy targeting Eph-B4-Ras-GAP-mTOR signaling
may represent a viable therapeutic approach for VOGM and, perhaps, CM-AVM spectrum
lesions.
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MAIN TABLES AND LEGENDS
Table 1. Enrichment of damaging de novo mutations in chromatin modifiers
intolerant to LoF mutation in VOGM
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Table 2. Transmitted mutations in EPHB4 and CLDN14 in VOGM
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FIGURES AND LEGENDS
Figure 1. Protein-altering de novo KEL mutations in Vein of Galen malformation
(VOGM)
(A) Representative digital subtraction angiography images demonstrating mural and
choroidal VOGMs in KVGAM45-1 and KVGAM10-1, respectively.
(B) Pedigrees depicting kindred structures. Note that probands carrying de novo
mutations in KEL are the only members of families KVGAM45 and KVGAM10
with VOGMs; none of the family members in these two families have any disease
phenotypes or cutaneous manifestations. Red ‘D’ denotes protein-altering
mutation, ‘+’ denotes wild type sequence.
(C) Mutations identified by exome sequencing were confirmed by direct PCR
amplification with custom primers followed by Sanger sequencing.
(D) Linear representation of the KEL polypeptide, with functional domains as dark
rectangles. Amino acid modifications are mapped (in red) on the protein structure.
Conservation of the wild-type amino acid substituted by the missense mutations is
depicted below. TM = Transmembrane domain.
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Figure 1. Protein-altering de novo KEL mutations in Vein of Galen malformation
(VOGM)
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Figure 2. Damaging de novo mutations in chromatin modifiers in VOGM
(A) Magnetic resonance angiographies and a digital subtraction angiography
reconstruction demonstrating VOGM in probands from four pedigrees.
(B) Pedigree structures of VOGM kindreds. For each kindred, the gene and mutation,
the angiographic image, and pedigree structure are shown. Subjects with atypical
capillary malformations are denoted by blue symbols. Red ‘D’ denotes damaging
mutation, ‘+’ denotes wild type sequence.
(C) Linear representation of functional domains of SIRT1, KMT2D, SMARCA2, and
KAT6A, with location of VOGM mutations. Functional domains are represented
by dark rectangles. Amino acid changes (red) are located on the protein structure.
For missense mutations, phylogenetic conservation of the wild-type amino acid is
shown, with the mutated amino acid in yellow. SIR2 = Sirtuin catalytic domain,
SIR2 Domain; PHD = Zinc Finger PHD type; MOZ_SAS = Histone
acetyltransferase domain, MYST-type; zf-H = PHD-like zinc binding domain;
FYRN = F/Y-rich domain - F/Y-rich N-terminus motif; FYRC = F/Y-rich domain
- F/Y-rich C-terminus motif; SET = Su(var)3-9, Enhancer-of-zeste and Trithorax;
QLQ = Glutamine-Leucine-Glutamine domain; HAS = Helicase-SANT associated
domain; BRK = BRK domain; SNF2_N = SNF2-related, N-terminal domain;
Hel_C = Helicase C-terminal domain; SnAC = Snf2-ATP coupling, chromatin
remodeling complex; BD = Bromodomain.
(D) Schematic of histone mark modifications by SIRT1, KMT2D, SMARCA2, and
KAT6A.
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Figure 2. Damaging de novo mutations in chromatin modifiers in VOGM
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Figure 3. Exome-wide significant enrichment of rare damaging transmitted
mutations in EPHB4 and CLDN14
(A) Quantile-quantile plots of observed vs. expected binomial test p-values for rare
damaging (D-mis+LoF) variants with MAF ≤ 2 x 10-5 in the Genome Aggregation
database (gnomAD) in LoF-intolerant genes (pLI ≥ 0.9).
(B) Quantile-quantile plots of observed vs. expected binomial test p-values for rare
damaging (D-mis+LoF) variants with MAF ≤ 2 x 10-5 in gnomAD for all genes.
MAF = Minor allele frequency; D-mis = Missense mutations predicted to be
deleterious per MetaSVM; LoF = Canonical loss-of-function mutations (stopgains, stop-losses, frameshift insertions or deletions, and canonical splice site
mutations).
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Figure 4. Damaging EPHB4 mutations in choroidal VOGM
(A) Vascular imaging of probands from coronal reconstruction of computed
tomography and magnetic resonance angiography demonstrating VOGMs.
(B) Pedigree structures of the kindreds, showing gene, mutation, and angiographic
image. A carrier with atrial septal defect in family KVGAM 33 is in yellow. Red
‘D’ denotes damaging mutation, ‘+’ denotes wild type sequence.
(C) Eph-B4 functional domains (dark rectangles) with location of VOGM mutations
(red), and phylogenetic conservation of wild-type amino acid (yellow) at each
mutated position. LB = ligand binding domain; CRD = Cysteine-rich domain;
FNIII = Fibronectin III domain; TM = Transmembrane domain; TK = Tyrosine
kinase domain; SAM = Sterile alpha motif.
(D) Representative immunoblots showing effects of Ala509Gly, Lys650Asn, and
Phe867Leu mutations on resting state Eph-B4 tyrosine phosphorylation in HEK
293T cells, analyzed by immunoprecipitation (IP) with HA-Tag antibody
followed by immunoblot (IB) with anti–p-tyrosine (p-Tyr) and HA-Tag
antibodies. Blot demonstrates reduced p-Tyr content in Lys650Asn, with none
detectable in Phe867Leu.Representative immunoblot demonstrating binding of
Eph-B4 constructs by Ras-GAP.
Ras-GAP protein was co-immunoprecipitated with Eph-B4 mutants. Ras-GAP
binding to Lys650Asn and to Phe867 was markedly reduced and abrogated,
respectively.

53

Figure 4. Damaging EPHB4 mutations in choroidal VOGM
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Figure 5. Damaging CLDN14 mutations in VOGM
(A) Representative images from digital subtraction angiographies and magnetic
resonance angiography demonstrating VOGMs of the probands.
(B) Pedigree structures indicating genotypes and phenotypes as described in Figure
2.
(C) Linear representation of Claudin-14 functional domains (dark rectangles) with
location of VOGM mutations (in red). Conservation of the wild-type amino acid
is shown. TM = Transmembrane domain; C = cytoplasmic loop; E = extracellular
loop.
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SOURCE
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This paper
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CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will
be fulfilled by the Lead Contact, Dr. Kristopher T. Kahle (kristopher.kahle@yale.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Patient Subjects
All procedures in this study comply with Yale University’s Human Investigation
Committee (HIC) and are Human Research Protection Program. Written informed consent
was obtained from all adult participants. Parent or legal guardian authorization was
obtained in writing for sample collection of all minors in this study. Inclusion criteria
included male or female patients with clearly defined mural or choroidal VOGMs,
radiographically-confirmed by both a neurosurgeon and neuroradiologist from an
angiogram or magnetic resonance angiogram, along with their family members. Fifty-five
probands diagnosed with VOGM were included in this study, of which 52 were parentoffspring trios. Among these 55 VOGM probands, 65.5% were female, 76.4% were selfreported Europeans, and 56.4% had a family history of cutaneous vascular abnormalities.
(Supplementary Table 1).

Controls consist of 1,789 unaffected siblings of autism cases and unaffected parents from
the Simons Foundation Autism Research Initiative Simplex Collection (SSC)(Fischbach
and Lord, 2010; Iossifov et al., 2014; Krumm et al., 2015; O'Roak et al., 2011; Sanders et
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al., 2012). Only the unaffected siblings and parents, as designated by SSC, were included
in the analysis and served as controls for this study. Permission to access to the genomic
data in the SCC on the National Institute of Mental Health Data Repository was obtained.
Written informed consent for all participants was provided by the Simons Foundation
Autism Research Initiative.

Whole Exome Sequencing and Variant Calling
Exon capture was performed on genomic DNA samples derived from saliva or blood using
Roche SeqCap EZ MedExome Target Enrichment kit or IDT xGen target capture kit
followed by 99 base paired-end sequencing on the Illumina HiSeq 2500 platform. Sequence
reads were aligned to the human reference genome GRCh37/hg19 using BWA-MEM (Li,
2014) and further processed to call variants following the GATK Best Practices workflow
(McKenna et al., 2010). Variants were annotated with ANNOVAR (Wang et al., 2010a)
and MetaSVM (Dong et al., 2015) was used to predict the deleteriousness of nonsynonymous variants (herein referred to as D-mis). All variants covered by independent
aligned sequencing reads with a depth of 8x or greater were visualized in silico to eliminate
false positives.

De novo mutations were called using TrioDeNovo (Venugopal, 2014). Candidate de novo
mutations were further filtered based on the following criteria: (1) exonic or splice-site
variants; (2) read depth (DP) of 10 in the proband and both parents; (3) genotype quality
(GQ) score ≥ 20; (4) minium proband alternative read depth of 5; (5) proband alternative
allele ratio ≥ 28% if having < 10 alternative reads or ≥ 20% if having ≥ 10 alternative reads;
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(6) alternative allele ratio in both parents ≤ 3.5%; (8) in-cohort allele frequency ≤ 4 x 10-4
for controls and MAF ≤ 4 x 10-4 in gnomAD for cases due to limited cohort size.

For rare transmitted dominant variants, only LoF mutations (stop-gains, stop-losses,
canonical splice-sites, and frameshift indels) and D-mis mutations (missense mutations
predicted deleterious by MetaSVM) were considered potentially damaging for subsequent
one-tailed binomial analysis and filtered using the following criteria to reduce false
positives: (1) GATK variant quality score recalibration (VQSR) of PASS, (2) MAF ≤ 2 x
10-5 in gnomAD (calculated based on combined dataset of WES and WGS data from
gnomAD database, Lek et al. 2016), (3) DP ≥ 8 independent reads, and (4) GQ score ≥ 20.
Transmitted recessive variants were filtered for rare (MAF ≤ 10-3 in gnomAD)
homozygous and compound heterozygous variants using the same criteria described above.

Candidate mutations were confirmed by PCR amplification followed by Sanger sequencing
(primer sequences available on request).

METHOD DETAILS

Kinship Analysis
Pairwise proband relatedness and pedigree information of trios were confirmed using
KING (Manichaikul et al., 2010) by estimating kinship coefficient and calculating identityby-descent (IBD). The shared pairwise IBD segments in 45 European probands were
detected using Beagle v3.3.2 (Browning and Browning, 2011).
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De Novo Mutation Expectation Model
We used a sequence context probability model to derive the per-gene probability of
observing a de novo mutation by chance as previously described (Samocha et al., 2014). In
brief, for each base in the exonic region, the probability of observing each of the three
possible single nucleotide changes was determined. The coding consequence of each
possible mutation was determined, and then these probabilities of mutations were summed
for each variant functional class (synonymous, missense, nonsense, canonical splice site,
frameshift, and stop-lost) to create a per-gene probability of mutations. The probability of
a frameshift mutation was determined by multiplying the probability of a nonsense
mutation by 1.25 as described previously (Samocha et al., 2014). In-frame insertions and
deletions are not currently accounted for by this framework and were not included in the
analysis. The per-gene probability for each functional class was adjusted to control for
sequencing coverage. Due to the difference in exome capture kits, DNA sequencing
platforms, and variable sequencing coverage between case and control cohorts, the
expected number of de novo mutations was estimated by adjusting for sequencing depth in
52 case trios and 1,789 autism control trios separately.

De Novo Enrichment Analysis and Variant Stratification
Rather than using the variant calls in controls published in the SSC study (Krumm et al.,
2015), we downloaded the bam files from the SSC, reanalyzed the data, and filtered the
control vcf file using the same filtering criteria as what was used in our case cohort. A onetail Poisson test was used to compare observed number of de novo mutations across each
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variant class to expected number under the null hypothesis. R package ‘denovolyzeR’
(Ware et al., 2015) was used to perform the analyses. The Benjamini-Hochberg method
was used to correct for multiple testing while taking into account all genes (N = 18,989)
and calculate adjusted p-values. A gene was considered significant if Benjamini-Hochberg
adjusted p-value is £ 0.05. All genes represented in this dataset were annotated with arteryspecific and brain-specific expression values in a form of reads per kilobase transcript per
million reads (RPKM) from the GTEx database (https://gtexportal.org/home/). Genes
harboring de novo mutations were also annotated with human brain specific expression
data obtained during the first four weeks of development (Gerrard et al., 2016) in the form
of quantile rank based on transcript per kilobase million (TPM), indicating the relative rank
of expression level within human genome. The final dataset was analyzed for recurrently
affected genes, and all variants in genes affected by a single de novo mutation were
stratified. LoF variants were ranked based on pLI (from highest to lowest).

QUANTIFICATION AND STATISTICAL ANALYSIS

Estimation of the Number of Damaging De Novo Mutations in LoF-intolerant
Chromatin Modifiers
One million permutations were performed to derive the empirical distribution of the
number of damaging de novo mutation in the LoF-intolerant chromatin modifier genes. For
each permutation, the number of observed damaging de novo mutations in all genes (n =
19) was randomly distributed across the exome, weighted according to the de novo
probabilities of damaging mutations. The empirical p-value is calculated as the proportion
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of times that the number of damaging de novo mutations in the LoF-intolerant chromatin
modifier genes is greater than or equal to the observed number (n = 4). The average number
of damaging de novo mutations in the LoF-intolerant chromatin modifier genes is also
calculated.

Binomial Analysis
Independent binomial tests were used to compare the expected and observed counts of rare
variants in each gene. The expected number of rare damaging variants is determined by
taking the fractional length of a gene (in base pairs) relative to the entire exome and
multiplying this by the total number of rare damaging variants. This represents the expected
occurrence of sporadic mutations in each gene without considering the influences of
selection pressure or precedents of ethnic background. Inputs for this test were those with
inferred pathogenicity, including missense mutations called deleterious per MetaSVM and
inferred LoF mutations (stop-gains, stop-losses, frameshift insertions/deletions, or
canonical splice site mutations). Binomial analysis for mutational enrichment did not
include non-frameshift insertions or deletions. The Benjamini-Hochberg method was
performed taking into account all genes (N = 18,989 for CLDN14) or all LoF-intolerant
genes (N = 3,230 for EPHB4 and CAD) as described above and the significance cutoff was
0.05. We reported genes that reached a more stringent Bonferroni multiple testing cutoff
of 2.63 × 10-6 (= 0.05/18,989) or 1.55 x 10-5 for binomial testing of all genes or LoFintolerant genes, respectively.
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Pathway Analysis
Inputs for this analysis were LoF-intolerant genes (pLI ≥ 0.9) harboring damaging de novo
mutations and/or rare (MAF ≤ 2 x 10-5) damaging transmitted mutations, as well as genes
with significant burden of de novo (KEL) or transmitted mutation (EPHB4 and CLDN14)
(n = 128 genes) into Ingenuity Pathway Analysis (IPA, Apr 2018). Core analysis using
Ingenuity Knowledge Base (Gene Only) as the reference set was performed. P-value was
calculated using a one-tailed Fisher’s exact test reflecting the likelihood that the overlap
between the input and a given gene set is due to random chance. In individual based casecontrol analysis, ethnicity-matched case and control samples were filtered using the same
criteria. Individuals carrying variants of interest in case and control groups were tallied
separately, and the p-value was obtained from a one-tailed Fisher’s exact test. In binomial
pathway analysis, the observed number of rare damaging variants in LoF-intolerant genes
that belong to statistically significant canonical pathways of interest were compared to the
expected number of mutations in each set using a one-tailed binomial test. Gene sets of
canonical pathways were obtained from IPA. The expected number of mutations in a given
gene set is calculated as the formula below:

Expected number of mutations = N×

:;<; =;> Gene

Length
?<>@A;BC<> :;<;D Gene Length

Where N denotes total number of rare damaging de novo and transmitted mutations in
intolerant genes as well as genes with significant burden of de novo and transmitted
mutations.
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Interactome Construction
We input all genes contributing to the significantly enriched pathway to String (version
10.5) (Szklarczyk et al., 2015). For organism, Homo sapiens was selected. For each
displayed interaction, active interaction sources were restricted to experiments, and the
maximum number of interactors was limited to 50.

In Silico Modeling of Mutational Effects on Protein Structure
The sequence for all available modeled human proteins was downloaded from Uniprot
(Apweiler et al., 2004). The stereochemical parameters of VOGM-associated mutations
were analyzed using PROCHECK (Laskowski et al., 1993) and PROSA (Wiederstein and
Sippl, 2007), and the final models were chosen based on the lowest energy function score
(Dope) within the modeling program. The mutations were constructed and the free energy
of change calculated (ΔΔG) in silico using the ICM mutagenesis (Abagyan et al., 1994).

Cell Culture
HEK 293T cells were passaged at 80-90% confluence on high glucose DMEM (Dulbecco’s
modified Eagle’s medium, Gibco Life Technologies, Waltham MA, USA) supplemented
with 10% fetal bovine serum (FBS, Gibco Life Technologies Waltham MA, USA), Lglutamine, and penicillin/streptomycin.

Mutagenesis of Eph-B4 and Plasmid Transfection
A wild-type mouse EPHB4 cDNA was sub-cloned into the pShuttle-IRES-hrGFP-2
plasmid vector with HA-Tag sequence (Protack et al., 2017). The QuikChange II Site-
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Directed Mutagenesis Kit (Aligent Technologies, Santa Clara CA, USA) was used to
generate isolated single amino-acid changes within the EPHB4 ORF (A509G, K650N,
F867L). All mutant constructs were sequenced to confirm successful mutagenesis. The
wild-type EPHB4, the mutant constructs, and empty vector were individually transiently
transfected into HEK 293T cells using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA, USA) according to its standard protocol. DNA complexes were
removed after 5 h and replaced with fresh complete medium. After 48 hours, the medium
was aspirated and the cells starved for 18 h in serum-free conditions.

Co-immunoprecipitation and Western Blotting
Cell lysates were prepared using NP40 lysis buffer (50 mM Tris, pH7.5; 1% Nonidet P-40;
150 mM NaCl; 10% Glycerol) containing protease and phosphatase inhibitor cocktail
(Roche, Basel, Switzerland). Protein concentrations were measured with DC Protein Assay
Reagents (Bio-Rad, Hercules CA, USA). For immunoprecipitation, equal amounts of cell
lysates were incubated with Sepharose beads linked to anti-HA-Tag antibody (Cell
Signaling Technology, Danvers, MA, USA) overnight at 4 °C. Immunoprecipitated protein
complexes were separated on SDS-PAGE gel and analyzed by Western blotting using
following antibodies: anti-phosphotyrosine P-Tyr-100, anti-HA-Tag, (Cell Signaling
Technology, Danvers MA, USA), anti-Ras GAP (Santa Cruz Biotechnology, Dallas TX,
USA). Band intensities were quantified using ImageJ software (Schneider et al., 2012).
Statistical analyses were performed using Prism 7 software (GraphPad Software, La Jolla
CA, USA).
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Zabramski, Brian P. Walcott, Christopher J. Stapleton, Beverly Aagaard-Kienitz, Georges
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SUPPLEMENTARY FIGURES
Supplementary figure 1. VOGM type and representative imaging for probands,
Related to Table 2
Representative images of 3-Tesla time-of-flight magnetic resonance angiography or digital
subtraction angiography for all patients with available imaging, with patient codes and
VOGM subtype. In cases for which imaging was not available, VOGM subtype was
ascertained from detailed transcripts of angiographies during or before endovascular
treatment of VOGM.
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Supplementary figure 2. Chromatogram alignments and segregation of select
candidate variants, Related to Table 2 and Figure 2, 4, and 5
Mutations identified by exome sequencing were confirmed by direct PCR amplification
with custom primers followed by Sanger sequencing.
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Supplementary figure 3. Cutaneous manifestations in VOGM probands and family
members, Related to Figure 4 and 5
Atypical capillary malformation on the posterolateral aspect of the distal third of the thigh
(A) and left cheek (B) of VGAM115-2. Panel C demonstrates an atypical capillary
malformation on left flank of VGAM115-4 – both individuals depicted in panels A-C carry
EPHB4 c.1295_1296del; p.Glu432fs. Atypical capillary malformations on the angle of the
jaw and superior right thorax of KVGAM42-1 (D) and KVGAM42-2 (E). Both individuals
depicted in panels DE carry RASA1 c.2125C>T; p.Arg708*. (F). Atypical capillary
malformation on the posterolateral aspect of the forearm in VGAM114-5, carrier of
EPHA4 c.2347G>A; p.Gly783Ser. (G). Nuccal atypical capillary malformation in a
proband harboring CLDN14 p.(Val143Met) (H). Lumbar atypical capillary malformation
in the same proband depicted in panel G. (I). Nuccal atypical capillary malformation in the
sister of the proband depicted in panels G and H, also harboring CLDN14 p.Val143Met.
(J). Atypical capillary malformation in the thigh of the mother of individuals depicted in
panels G-I, carrying and transmitting CLDN14 p.Val143Met.
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Supplementary figure 4. In silico modeling of CLDN14 mutations, Related to Figure
5
(A) In silico modeling of p.Ala113Pro. Ala113 is the first residue of Helix-3 and lies
between P112 and K114 at the interface of Claudin-14 and the cytoplasmic side of
the lipid bilayer. Just preceding helix-3 is the loop that connects helix-2 and -3, on
which posttranslational modification sites are present, including for palmitoylation.
The presence of Proline in an alpha helix can result in helix distortion since it lacks
the backbone NH to establish the hydrogen bonding necessary to complete the Hbond chain. Additionally the steric or rotamer effects prevent Proline from adopting
helical geometry. The two adjacent Proline residues 112 and 113 likely influence
the conformation of the helix 2-3 connector loop and destabilize the initial portion
of helix-3. Calculated ΔΔG of A113P is 1.08 Kcal/mol.
(B) In silico modeling of p.Val143Met located towards the end of helix-3 at the outer
leaflet of the lipid bilayer. The Valine side chain is tightly packed against b sheets,
being surrounded by the hydrophobic side chains of L164, I160 and V144. The
V143M mutation (ΔΔG = 0.6 Kcal/mol) results in steric clash of the larger
Methionine side chain with the beta sheets.
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Supplementary figure 5. Mutations affecting other members of the Ephrin family in
VOGM patients displaying CM-AVM-like cutaneous manifestations, Related to
Figure 3
(A) Representative magnetic resonance angiography and digital subtraction
angiography images demonstrating choroidal Vein of Galen malformations in
probands.
(B) Pedigrees depicting kindred structure and phenotypic variance. Note the presence
of atypical capillary malformations represented by blue symbols in both parents
transmitting EFNB2 and EPHB4 mutations in families VGAM101 and
VGAM114. Red ‘D’ denotes damaging mutation, ‘+’ denotes wild type sequence.
(C) Linear representation of affected Ephrin polypeptides. Functional domains are
represented by dark rectangles. Amino acid modifications are mapped on the
protein structure in red lettering. Conservation of the wild-type amino acid
substituted by the four deleterious missense mutations is depicted on the right of
each molecule schematic. LB = ligand binding domain; CRD = Cysteine-rich
domain; FNIII = Fibronectin III domain; TM = Transmembrane domain; TK =
Tyrosine kinase domain; SAM = Sterile alpha motif.
(D) In silico modelling of the repercussion of Eph-A4 p.Gly783Ser. Gly783 lies at the
base of a flexible loop in Eph-A4.
(E) The Gly-to-Ser substitution at this position (ΔΔG 0.6Kcal/mol) is predicted to
affect loop stability.
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Supplementary figure 5. Mutations affecting other members of the Ephrin family in
VOGM patients displaying CM-AVM-like cutaneous manifestations, Related to
Figure 3
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Supplementary figure 6. Damaging ACVR1 mutations in mural Vein of Galen
malformation, Related to Figure 3
(A) Representative images from digital subtraction angiographies demonstrating mural
Vein of Galen Malformations in probands.
(B) Pedigrees depicting kindred structure and phenotypic variance. Blue symbols
represent atypical capillary malformations in individuals harboring the
c.1118A>G; p.Asn373Ser mutation. Yellow coloring of half the symbol denotes
concomitant presence of an atrial septal defect and (asterisk) partial anomalous
pulmonary venous return in the proband of family KVGAM44. Red ‘D’ denotes
damaging mutation, ‘+’ denotes wild type sequence.
(C) Linear representation of the ACVR1 polypeptide, with functional domains
represented as dark rectangles. Amino acid modifications are mapped (in red) on
the protein structure. Conservation of the wild-type amino acid substituted by the
two deleterious missense mutations is depicted below each. AR = activin receptor;
TM = Transmembrane domain; KD = Kinase domain
(D) In silico modelling of p.Asn373Ser. Asn373 in a 3D model of ACVR1.
(E) Predicted energetically costly (ΔΔG 2.9Kcal/mol) loss of hydrogen bond formation
between the Asn373 side chain and backbone atoms of Gly356, Lys243, Arg375
and the side chain of Ser244 caused by Asn373 substitution to serine.
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Supplementary figure 6. Damaging ACVR1 mutations in mural Vein of Galen
malformation, Related to Figure 3
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Supplementary figure 7. Interactome of mutated Ephrin receptor signaling genes in
VOGM, Related to Table 2 and Figure 3
All 7 genes (highlighted) contributing to the significant result of the Ephrin receptor
signaling pathway in IPA pathway analysis were input into String. These 7 genes are
mapped into a single experimentally supported STRING interactome.

76

Supplementary figure 8. The genomic landscape of VOGM, Related to Figure 3
Schematic representation of signaling between two primitive endothelial cells showing
contact-mediated interaction between the membrane-bound ligand Ephrin-B2 in the upper
cell and its receptor, Eph-B4, in the lower cell. The figure depicts crosstalk between EphB4, its effector and binding partner RASA1, and activin type 1 receptors mediated by noncanonical TGF-b signaling. Mutations discovered in our cohort affecting EPHB4, EFNB2,
and ACVR1 are shown in red, and previously reported mutations in RASA1, EPHB4, and
ENG in VOGM patients are indicated in black. RASA1 p.Arg709* (highlighted in yellow)
is the sole RASA1 mutation detected in our cohort.
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SUPPLEMENTARY TABLES
Supplementary Table 1. VOGM patient clinical and demographic characteristics, Related to STAR Methods
Type of VOGM
Choroidal (%)
37 (67.27)

Mural (%)
18 (32.73)

Grand Total (%)
55 (100.00)

Total

11 (29.73)
26 (70.27)
37 (100.00)

8 (44.44)
10 (55.56)
18 (100.00)

19 (34.55)
36 (65.45)
55 (100.00)

Neonate (0-30 days)

15 (40.54)
12 (32.43)

7 (38.89)
0 (0.00)

22 (40.00)
12 (21.82)

9 (24.32)
0 (0.00)
1 (2.70)
0 (0.00)
0 (0.00)
37 (100.00)

10 (55.56)
0 (0.00)
0 (0.00)
0 (0.00)
1 (5.56)
18 (100.00)

19 (34.55)
0 (0.00)
1 (1.82)
0 (0.00)
1 (1.82)
55 (100.00)

32 (86.49)
4 (10.81)
1 (2.70)
37 (100.00)

13 (72.22)
4 (22.22)
1 (5.56)
18 (100.00)

45 (81.82)
8 (14.55)
2 (3.64)
55 (100.00)

23 (62.16)
7 (18.92)

8 (44.44)
7 (38.89)

31 (56.36)
14 (25.45)

Total

7 (18.92)
37 (100.00)

3 (16.67)
18 (100.00)

10 (18.18)
55 (100.00)

European/Asian
European/Hispanic
Latin American/African American

29 (78.38)
3 (8.11)
1 (2.70)
1 (2.70)

13 (72.22)
1 (5.56)
1 (5.56)
0 (0.00)

42 (76.36)
4 (7.27)
2 (3.64)
1 (1.82)

1 (2.70)
0 (0.00)
0 (0.00)
2 (5.41)

0 (0.00)
2 (11.11)
1 (5.56)
0 (0.00)

1 (1.82)
2 (3.64)
1 (1.82)
2 (3.64)

37 (100.00)

18 (100.00)

Variable
Gender
Female
Male
Age at diagnosis
Prenatal

Postnatal

Infant (1 month-2 years)
Young child (3-6 years)
Child (7-12 years)
Adolescent (13-17 years)

Unknown
Total
Term vs. preterm delivery
Term (≥ 37 wks)
Preterm
Unknown
Total
Family history of cutaneous vascular abnormalities*
Yes
No
Unknown
Self-reported ethnicity
European
Mixed
Asian
African
Ashkenazi Jewish
Unknown
Total

Associated conditions
High output cardiac failure
23 (62.16)
1 (5.56)
Progressive macrocephaly
22 (59.46)
13 (72.22)
Hydrocephalus
24 (64.86)
9 (50.00)
Prominent facial or scalp vasculature
18 (48.65)
9 (50.00)
Structural cardiac abnormalities†
4 (10.81)
1 (5.56)
*History of vascular birthmarks was self-reported in most cases, including first and second-degree relatives.

55 (100.00)
Total
24 (43.64)
35 (63.64)
33 (60.00)
27 (49.09)
5 (9.09)

†Structural cardiac abnormalities include atrial septal defects, congenital valvular insufficiency, partial anomalous pulmonary venous return,
patent foramen ovale, patent ductus arteriosus, and congenital pulmonary artery stenosis.
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Supplementary Table 2. Summary sequencing statistics for the VOGM cases and control cohorts, Related to START Methods
Category
Cases*
Cases*
Controls
(xGen; N=88)
(MedExome; N=71)
(Roche V2; N=5,367)
Read length (bp)
99
99
50-94
# of reads per sample (M)
48.9
53.7
99.7
Median coverage at each targeted base (X)
54.4
37.2
67
Mean coverage at each targeted base (X)
59.4
43.8
79.1
% of all reads that map to target
60.70%
48.30%
57.60%
% of all bases that map to target
46.10%
39.10%
49.00%
% of targeted bases read at least 8x
98.40%
96.30%
94.60%
% of targeted bases read at least 10x
98.00%
95.00%
93.40%
% of targeted bases read at least 15x
96.30%
89.80%
89.90%
% Mean error rate
0.30%
0.30%
0.40%
*88 VOGM samples were sequenced using the xGen Exome Research Panel v1.0 capture reagent (IDT). The remaining cases were
sequenced using the MedExome capture reagent. 8X, 10X and 15X were comparable across the platforms.

Supplementary Table 3. Enrichment of de novo variant types in 52 VOGM and 1,789 control trios, Related to Table 1
Cases, N = 52
Observed
N

Rate

Controls, N = 1,789

Expected
N

Rate

Observed

Enrichment p-value

N

Rate

All Genes

Expected
N

Rate

Enrichment p-value

All Genes

Total

63

1.21

58.10

1.12

1.08

0.28

Total

1830

1.02

1949.9

1.09

0.94

1.00

Syn

15

0.29

16.50

0.32

0.91

0.68

Syn

484

0.27

549.6

0.31

0.88

1.00

D-Mis

14

0.27

6.80

0.13

2.05

0.01

D-Mis

222

0.12

232.8

0.13

0.95

0.77

T-Mis

29

0.56

29.70

0.57

0.98

0.58

T-Mis

974

0.54

993.3

0.56

0.98

0.73

LoF

5

0.10

5.10

0.10

0.98

0.58

LoF

150

0.08

174.3

0.10

0.86

0.97

Damaging

19

0.37

12.00

0.23

1.59

0.04

Damaging

372

0.21

407.1

0.23

0.91

0.96

Syn = Synonymous single nucleotide variant; D-Mis = Missense variants with “D” annotation per MetaSVM;
T-Mis = Missense variants with “T” or “.” annotation per MetaSVM; LoF = Predicted loss-of-function
variants (canonical splice site, frameshift indels, stop gains, and stop losses); Damaging = D-mis and/or LoF.
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Supplementary Table 4. De novo burden analysis comparing cases to controls, Related to Table 1
# of de novo mutations

# of de novo mutations
per subject

Cases

Controls&

Cases

Controls&

N=52

N=1,789

N=52

N=1,789

Total

14

597.9

0.27

0.33

0.5

Syn

2

150.7

0.04

0.08

0.38

NA

Mis

11

402.1

0.21

0.22

0.96

2.06 (0.45 - 9.41)

D-Mis

6

75.9

0.12

0.04

0.03

5.96 (1.17 - 30.22)

LoF

1

45.1

0.02

0.03

1

1.67 (0.15 - 18.85)

Damaging

7

121.0

0.13

0.07

0.12

4.36 (0.89 - 21.37)

Binomial P-value*

Odds ratio (95% CI)#

LoF-intolerant genes (n = 3,230)
NA

All chromatin genes (n = 547)
Total

4

77.1

0.08

0.04

0.42

NA

Syn

0

14.2

0.00

0.01

1

NA

Mis

3

55.8

0.06

0.03

0.51

NA

D-Mis

3

14.2

0.06

0.01

3.4x10-3

NA

LoF

1

7.1

0.02

0.00

0.57

NA

Damaging

4

21.4

0.08

0.01

8.6x10-4

NA

LoF-intolerant chromatin genes (n = 272)
Total

4

55.8

0.08

0.03

0.16

NA

Syn
Mis

0
3

10.7
41.5

0.00
0.06

0.01
0.02

1
0.26

NA
NA

D-Mis
LoF

3
1

8.3
3.6

0.06
0.02

0.00
0.00

9.0x10-5
0.3

NA
NA

Damaging

4

11.9

0.08

0.01

3.9x10-6

NA

&

Due to the difference in the de novo mutation rates between cases and controls, we adjusted the de novo mutation rate in controls to match
the per-person rate by dividing the original rate per control by 0.84 (=1.02/1.21).
* The p-values compare the number of de novo mutations between 52 case trios and 1,789 control trios using a two-tailed binomial exact test
as shown previously (Sanders et al. 2012 Nature; Zaidi et al. 2013 Nature).
The odds ratio calculates the proportion of de novo mutations in a specific category to synonymous de novo mutations and then compare
these ratios in case trios versus control trios. NA, not applicable.
#
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SIRT1

SMARCA2

KVGAM20*

KVGAM29

9:2086866:G:T

10:69666624:TC:T

12:49420060:C:T

8:41832271:G:A

Coordinate (hg19)

European

European

European

Mexican

Ethnicity

De novo

De novo

De novo

De novo

Inheritance

p.Arg855Leu < 4.06E-06 1.00

p.Arg341fs5 < 3.63E-06 0.95

p.Cys5230Tyr < 4.06E-06 1.00

p.Thr478Ile < 4.11E-06 1.00

5.57

0.58

3.10

2.14

Missense
Z-score

.
26.5

None

22.4

24.2

Choroidal

Choroidal

D

Mural

N/A Choroidal

D

D

CADD MetaS Type of
VM VOGM

NicolaidesBaraitser
syndrome (AD)

Kabuki
syndrome (AD)

Mental
retardation (AD)

OMIM
phenotype

n

y

y

y

n

y

y

y

Cutaneous
Vascular
manifestations
cutaneous
or non CNS
manifestations
AVMs in
on proband?
kindred?

* This subject also carried a p.Val143Met mutation in CLDN14 transmitted from mother
** For variants not observed in public databases, their minor allele frequency is calculated as less than 1 out of total number of alleles sampled at the closest locus with allele number available

KMT2D

KAT6A

KVGAM38

KVGAM26

Gene

Proband code

gnomAD
AA Change combined pLI
MAF**

n

y

n

n

n

n

n

n

N/A

n

y

y

Vascular
Vascular
Concordance
Birthmarks/
Birthmarks/A with mutation
AVMs on
VMs on father
type
mother

Supplementary Table 5. Damaging de novo mutation in loss-of-function intolerant chromatin modifier genes in 55 cases, Related to Table 1
Salient genetic information
Salient clinical and segregation information

Supplementary Table 6a. Case-control analysis of gene burden of damaging variants in all probands
versus 3,578 Autism parental controls, Related to Figure 3
Case
Control
Gene
# mutant allele # ref allele # mutant allele # ref allele Fisher p value Odds ratio
EPHB4
4
106
3
7,153
1.68E-06
89.97
MYH7
3
107
0
7,156
3.38E-06
Inf
AOC2
3
107
0
7,156
3.38E-06
Inf
CLDN14
3
107
0
7,156
3.38E-06
Inf
OTOG
2
108
0
7,156
2.27E-04
Inf
NALCN
2
108
0
7,156
2.27E-04
Inf
LTBP2
2
108
0
7,156
2.27E-04
Inf
MLH3
2
108
0
7,156
2.27E-04
Inf
PKM
2
108
0
7,156
2.27E-04
Inf
TPSG1
2
108
0
7,156
2.27E-04
Inf
Supplementary Table 6b. Case-control analysis of gene burden of damaging variants in all probands
versus ExAC controls, Related to Figure 3
Case
Control
Gene
# mutant allele # ref allele # mutant allele # ref allele Fisher p value Odds ratio
EPHB4
4
106
92
121,318
1.98E-06
49.76
AOC2
3
107
39
121,373
8.07E-06
87.26
CLDN14
3
107
50
120,946
1.65E-05
67.82
MPST
2
108
17
116,829
1.48E-04
127.26
DNAH12
2
108
37
121,367
5.89E-04
60.74
EMILIN3
2
108
40
121,192
6.85E-04
56.11
ABHD17A
2
108
42
118,070
7.91E-04
52.06
PRKDC
1
109
0
121,412
9.05E-04
Inf
SEPT1
1
109
0
121,412
9.05E-04
Inf
ADGRL4
2
108
50
120,618
1.06E-03
44.67
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Ingenuity Canonical Pathways

Axonal Guidance Signaling

nNOS Signaling in Skeletal Muscle Cells

GABA Receptor Signaling

Netrin Signaling

FcγRIIB Signaling in B Lymphocytes

Corticotropin Releasing Hormone Signaling

G Beta Gamma Signaling

Synaptic Long Term Depression

Ephrin Receptor Signaling

Androgen Signaling

CCR5 Signaling in Macrophages

Rank

1

2

3

4

5

6

7

8

9

10

11

2.40E-04

1.55E-04

7.59E-05

7.41E-05

5.62E-05

1.74E-05

6.92E-06

2.19E-06

1.41E-06

1.32E-07

6.61E-08

P-value

0.05

0.03

0.01

0.01

0.01

3.41E-03

1.36E-03

4.34E-04

2.81E-04

2.64E-05

1.33E-05

SLIT3, ITGB1, SHH, EPHB4, NGEF, ITSN1, EPHA4, KEL, SLIT2,
ADAMTS2, MET, EPHA6, SHANK2, RASA1, NRP1
CACNA1G, CACNG2, CACNA1B, RYR2, CACNA2D3, CACNA1A

Genes

0.05

0.04

0.04

0.04

0.05

0.05

0.08

0.09

CACNA1G,CACNG2,CACNA1B,CACNA2D3,CACNA1A

CACNA1G, CACNG2, CACNA1B, POLR2H, CACNA2D3, CACNA1A

ITGB1, EPHA6, NGEF, EPHB4, ITSN1, EPHA4, RASA1

CACNA1G, CACNG2, CACNA1B, RYR2, PPP2R2B, CACNA2D3, CACNA1A

CACNA1G, CACNG2, CACNA1B, CACNA2D3, CACNA1A, DNM2

CACNA1G, CACNG2, SHH, CACNA1B, KRT1, CACNA2D3, CACNA1A

CACNA1G, CACNG2, CD79B, CACNA1B, CACNA2D3, CACNA1A

CACNA1G, CACNG2, CACNA1B, RYR2, CACNA2D3, CACNA1A

0.07 CACNA1G, CACNG2, CACNA1B, GABRB1, KCNH2, CACNA2D3, CACNA1A

0.15

0.03

Corrected
Ratio
P-value

Supplementary Table 7. Significant pathways in Ingenuity ® Pathway Analysis including intolerant genes harboring damaging de novo mutations, damaging
rare transmitted mutations, and significantly mutated genes (KEL, EPHB4, CLDN14) (n = 128), Related to Table 1 and Figure 3
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Supplementary Table 8. Mutation burden in cases compared to European ethnicity-matched controls in IPA-determined significant pathways, Related to Table 1 and Figure 3
Control_Group
Pathway (# of intolerant genes)
Case_Carrier Case_NonCarrier CaseTotal Control_Carrier* Control_NonCarrier ControlTotal Enrichment Confident_Interval
Autism
nNOS Signaling in Skeletal Muscle Cells (n = 18)
4
41
45
196
2,690
2,886
1.34
[0.43, Inf)
Autism
Axonal Guidance Signaling (n = 161)
14
31
45
279
2,607
2,886
4.22
[2.29, Inf)
Autism
Ephrin Receptor Signaling (n = 73)
8
37
45
127
2,759
2,886
4.69
[2.15, Inf)
Autism
Androgen Signaling (n = 55)
4
41
45
193
2,693
2,886
1.36
[0.44, Inf)
Autism
CCR5 Signaling in Macrophages (n = 31)
3
42
45
138
2,748
2,886
1.42
[0.37, Inf)
Autism
Corticotropin Releasing Hormone Signaling (n = 57)
5
40
45
244
2,642
2,886
1.35
[0.5, Inf)
Autism
FcγRIIB Signaling in B Lymphocytes (n = 36)
3
42
45
149
2,737
2,886
1.31
[0.34, Inf)
Autism
G Beta Gamma Signaling (n = 53)
4
41
45
189
2,697
2,886
1.39
[0.45, Inf)
Autism
GABA Receptor Signaling (n = 45)
6
39
45
175
2,711
2,886
2.38
[0.97, Inf)
Autism
Netrin Signaling (n = 32)
4
41
45
212
2,674
2,886
1.23
[0.4, Inf)
Autism
Synaptic Long Term Depression (n = 65)
5
40
45
289
2,597
2,886
1.12
[0.42, Inf)
ExAC
nNOS Signaling in Skeletal Muscle Cells (n = 18)
4
41
45
3,145
33,532
36,677
1.04
[0.34, Inf)
ExAC
Axonal Guidance Signaling (n = 161)
14
31
45
3,878
32,799
36,677
3.82
[2.1, Inf)
ExAC
Ephrin Receptor Signaling (n = 73)
8
37
45
1,621
35,056
36,677
4.68
[2.18, Inf)
ExAC
Androgen Signaling (n = 55)
4
41
45
4,718
31,959
36,677
0.66
[0.22, Inf)
ExAC
CCR5 Signaling in Macrophages (n = 31)
3
42
45
2,138
34,539
36,677
1.15
[0.3, Inf)
ExAC
Corticotropin Releasing Hormone Signaling (n = 57)
5
40
45
3,466
33,211
36,677
1.20
[0.45, Inf)
ExAC
FcγRIIB Signaling in B Lymphocytes (n = 36)
3
42
45
2,321
34,356
36,677
1.06
[0.28, Inf)
ExAC
G Beta Gamma Signaling (n = 53)
4
41
45
2,726
33,951
36,677
1.22
[0.4, Inf)
ExAC
GABA Receptor Signaling (n = 45)
6
39
45
2,995
33,682
36,677
1.73
[0.71, Inf)
ExAC
Netrin Signaling (n = 32)
4
41
45
3,361
33,316
36,677
0.97
[0.32, Inf)
ExAC
Synaptic Long Term Depression (n = 65)
5
40
45
4,494
32,183
36,677
0.89
[0.34, Inf)
P values were calculated using the one-tailed Fisher's Exact Test. Values in red bold are P values exceeding the Bonferroni multiple-testing cutoff (0.05/(2x11) = 2.27E-03)
* ExAC database does not provide individual level information, number of damaging mutations in each gene set carried by each individual was assumed to be 1.

p-value
0.37
6.94E-05
8.36E-04
0.36
0.37
0.33
0.42
0.34
0.06
0.43
0.48
0.55
1.52E-04
7.33E-04
0.85
0.49
0.42
0.55
0.43
0.16
0.60
0.66
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7.14

2.52

20.12

1.04

348.77

1.07

3878

3967.08

0.98

Observed Expected Enrichment

372

Observed Expected Enrichment

21

Observed Expected Enrichment

18

Observed Expected Enrichment

0.93

p-value

0.11

p-value

0.45

p-value

3.02E-04

p-value

Ephrin receptor signaling

LoF-intolerant genes with damaging mutations in ExAC controls

LoF-intolerant genes with damaging mutations in autism controls

LoF-intolerant genes with synonymous mutations in VOGM cases

LoF-intolerant genes with damaging mutations in VOGM cases

2.90

3.45

8.17

0.49

141.56

1.17

1621

1611.57

1.01

Observed Expected Enrichment

166

Observed Expected Enrichment

4

Observed Expected Enrichment

10

Observed Expected Enrichment

p-value

0.41

p-value

0.02

p-value

0.96

p-value

7.28E-04

P values were calculated using the one-tailed binomial test comparing observed number of variants in LoF-intolerant genes that belong to statistically significant canonical pathways of interest to the expected number of mutations in each set (see Methods).
Values in bold red are P values exceeding the Bonferroni multiple-testing cutoff (0.05/(2x3) = 0.008)

LoF-intolerant genes with damaging mutations in ExAC controls

LoF-intolerant genes with damaging mutations in autism controls

LoF-intolerant genes with synonymous mutations in VOGM cases

LoF-intolerant genes with damaging mutations in VOGM cases

Axon guidance signaling

Supplementary Table 9. Gene burden in cases compared to expectation for axonal guidance and Ephrin receptor signaling pathways, Related to Table 1 and Figure 3
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6.66

8

1.2

Enrichment

0.35

p-value

Axonal Guidance Signaling (n = 161)

Autism

ExAC

6

6
39

39
45

45
2,726

197

33,951

2,689

36,677

2,886

1.92

2.10

[0.79,Inf)

[0.86,Inf)

Case_Carrier Case_NonCarrier CaseTotal Control_Carrier* control_NonCarrier ControlTotal Enrichment Confident_Interval

P values were calculated using the one-tailed Fisher's Exact Test. Bonferroni multiple-testing cutoff for this test is 0.05/2 = 0.025
* ExAC database does not provide individual level information, number of damaging mutations in each gene set carried by each individual was assumed to be 1.

Pathway

Axonal Guidance Signaling (n = 161)

Control_Sample

0.11

0.09

p-value

Supplementary Table 10b. Mutation burden in cases compared to European ethnicity-matched controls for axonal guidance pathway after removing genes in the ephrin signaling pathway, Related to Table 1 and Figure 3

P values were calculated using the one-tailed binomial test comparing observed number of variants in LoF-intolerant genes that belong to statistically significant canonical pathways of interest to the expected number of mutations in
each set (see Methods).

Expected

Observed

Supplementary table 10a. Gene burden in cases compared to expectation for axonal guidance pathway after removing genes in the ephrin signaling pathway, Related to Table 1 and Figure 3

LoF-intolerant genes with damaging mutations in VOGM cases
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LoF

Transmitted
Transmitted
Transmitted
Transmitted
Transmitted
Transmitted
Transmitted
Transmitted
Transmitted

VGAM105
VGAM115
KVGAM25
KVGAM33
KVGAM18
KVGAM55
KVGAM7
VGAM114
KVGAM45

KVGAM42 Transmitted

Supplementary Table 11. Mutations in genes in the Ephrin receptor signaling pathway, Related to Table 1 and Figure 3
gnomAD
Coding sequence
ExAC
Missense
Meta
Gene
Coordinate (hg19)
AA Modification
combined pLI
OMIM phenotype
CADD
variant
MAF*
Z-score
SVM
MAF*
ITGB1
chr10:33196073
N/A
Splice site
0.91
3.47
None
20.9
N/A
< 8.27E-06 < 4.15E-06
chr7:100417179
c.1295_1296del
p.Glu432fs1
.
D
< 9.06E-06 < 4.76E-06
chr7:100414876
c.1526C>G
p.Ala509Gly
3.30E-05 1.13E-05
Non-immune hydrops fetails
25
D
EPHB4
0.99
2.84
chr7:100410537
c.1950G>T
p.Lys650Asn
with/without atrial septal defect 29.9
D
< 8.24E-06 < 4.06E-06
chr7:100403202
c.2599T>C
p.Phe867Leu
31
D
< 9.03E-06 < 5.17E-06
NGEF
chr2:233745889
c.1909G>A
p.Asp637Asn
2.83E-05 1.22E-05 0.95
2.18
None
34
D
ITSN1
chr21:35260471
c.5033C>T
p.Thr1678Met
1.89E-05 8.13E-06 1.00
3.44
None
34
D
EPHA4
chr2:222299011
c.G2347G>A
p.Gly783Ser
3.15
None
34
D
< 8.28E-06 < 4.07E-06 1.00
EPHA6
chr3:96706498
c.775C>T
p.Arg259Cys
0.93
None
34
D
< 8.38E-06 < 3.23E-05 0.95
CM-AVM1; Parkes Weber
RASA1
chr5:86672323
c.2125C>T
p.Arg709*
2.96
Syndrome; Somatic basal cell
40
N/A
< 8.26E-06 < 3.23E-05 1.00
carcinoma

* For variants not observed in public databases, their minor allele frequency is calculated as less than 1 out of total number of alleles sampled at the closest locus with allele number available

LoF
LoF
D-mis
D-mis
D-mis
D-mis
D-mis
D-mis
D-mis

Inheritance

Mutation
Type

Proband
code
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Supplementary Table 12. Transmitted VOGM mutations in Mendelian AVM genes, Related to Figure 3
gnomAD
Family
Type of VOGM Ethnicity
Gene
Mutation
Domain affected
ExAC MAF*
pLI
MetaSVM
CADD
MAF*
&
KVGAM6
Mural
European
ACVR1
p.(G39S)
Activin receptor
3.24E-05
0.96
D
24.8
< 8.24E-06
KVGAM44
Mural
European
ACVR1&
p.(N373S)
Kinase domain
0.96
T
24.1
< 8.26E-06
< 4.07E-06
VGAM100
Choroidal
Mexican
ACVRL1
p.(R484Q)
Kinase domain
0.01
D
33
< 8.28E-06
< 3.24E-05
&
ACVR1 is a paralog of ACVRL1
* For variants not observed in public databases, their minor allele frequency is calculated as less than 1 out of total number of alleles sampled at the closest locus with
allele number available

Supplementary Table 13. Distribution of highly pathogenic mutations in VOGM patients with different subphenotypes, Related to Table 1, Figure 3, and STAR Methods
Proband
Code

Gender

KVGAM1
KVGAM10
KVGAM15
KVGAM18
KVGAM2

M
M
M
M
M

Postnatal
SubFetal Age
Gene
Age at
Phenotype at Diagnosis (weeks)
Diagnosis
European Choroidal
7 mo.
European Choroidal
34
KEL
European Choroidal
3 d.
European Choroidal
40
EPHB4
Undetermined Choroidal
33
CLDN14
European Choroidal
6 mo.
SIRT1
European Choroidal
5 mo.
European Choroidal
8 yr.
European Choroidal
19 d.
EPHB4
Ethnicity

KVGAM20

F

KVGAM22
KVGAM24
KVGAM25

F
M
M

KVGAM26

M

European

Choroidal

1 d.

KVGAM30
KVGAM31
KVGAM32
KVGAM33
KVGAM34
KVGAM35
KVGAM37
KVGAM38
KVGAM4

M
F
M
F
M
M
M
M
M

European
European
European
Mexican
European
European
European
Mexican
Undetermined

Choroidal
Choroidal
Choroidal
Choroidal
Choroidal
Choroidal
Choroidal
Choroidal
Choroidal

5 d.
11 mo.
7 d.
1 d.

KVGAM40

M

European

Choroidal

KVGAM52

F

European

Choroidal

32

KVGAM54
KVGAM55
KVGAM7
KVGAM8
KVGAM9

F
F
F
M
F

European
European
European
European
European

Choroidal
Mural
Choroidal
Choroidal
Choroidal

38
20

Amino Acid
Change

Type

p.Gln321*

stopgain

p.Phe867Leu

Dmis

p.Val143Met

Dmis

p.Arg341fs5

Frameshift deletion

p.Ala509Gly

Dmis

KMT2D p.Cys5230Tyr

Dmis

Proband with Relatives with
Capillary
Capillary
Malformation Malformation
n
n
De novo
n
y
n
y
Transmitted
n
y
n
n
Transmitted
y
y
De novo
n
n
n
n
Transmitted
n
n

Transmission

De novo

EPHB4

p.Lys650Asn

Dmis

Transmitted

KAT6A

p.Thr478Ile

Dmis

De novo

35
37
36
6 d.
2 d.
3 mo.

1 yr.

NGEF
ITSN1

p.Asp637Asn
p.Thr1678Met

Dmis
Dmis

Transmitted
Transmitted

ACVRL1
p.R484Q
CLDN14 p.Ala113Pro
EFNB2 p.Arg277His

Dmis
Dmis
Dmis

Transmitted
Transmitted
Transmitted

39
38

VGAM100

F

Mexican

Choroidal

34

VGAM101
VGAM104
VGAM107

M
M
F

European
European
European

Choroidal
Choroidal
Choroidal

36

VGAM108
VGAM109

M
M

European
Mexican

Choroidal
Choroidal

VGAM111

M

European

Choroidal

VGAM112
VGAM113
VGAM114
VGAM115
VGAM47
KVGAM11
KVGAM29

M
M
F
M
M
M
M

European
European
European
European
European
European
European

Choroidal
Choroidal
Choroidal
Choroidal
Choroidal
Mural
Mural

KVGAM3
KVGAM36

F
F

European
European

Mural
Mural

31

KVGAM41

M

European

Mural

14 mo.

KVGAM42
KVGAM43

F
M

Mexican
African

Mural
Mural

6 mo.
14 mo.

Other phenotypes
Neurodevelopmental delay
Pulmonary hypertension, neurodevelopmental delay
Patent ductus arteriosis, neurodevelopmental delay
Cryptorchidism, strabismus, cerebral palsy
n
n

n

n

n
n
n
n
n
n
n
y
n

y
n
y
y
n
n
y
n
n

n

y

n

n

n
Recurrent epistaxis
Pectus excavatum
Hypothyroidism, low set ears, long and everted palpebral fissures,
neurodevelopmental delay, seizures
Neurodevelopmental delay, seizures
Neurodevelopmental delay
n
Neurodevelopmental delay
Neurodevelopmental delay, attention deficit hyperactivity disorder
n
Neurodevelopmental delay
Neurodevelopmental delay, seizures
n
Cerebral palsy, hip dysplasia, visual impairment, gastroesaphageal
reflux disease, neurodevelopmental delay, seizures
n

n
n
n
n
n

y
n
y
y
n

n
n
Pulmonary valve stenosis, neurodevelopmental delay
Neurodevelopmental delay, seizures
Patent ductus arteriosis, patent foramen ovale, seizures

n

n

Strabismus

3 d.
4 d.

y
y
n

y
n
n

Hip dysplasia, neurodevelopmental delay, seizures
Cerebral palsy, neurodevelopmental delay
Medulloblastoma, seizures

2 mo.
3 d.

n
y

y
y

31

n

n

36

n
n
y
n
n
n
n

n
n
y
y
n
y
n

Asthma
Cerebral palsy, neurodevelopmental delay, seizures
Cerebral palsy, gastroesophageal reflux disease, renal agenesis,
precocious puberty, mitral insufficiency, neurodevelopmental delay,
seizures
n
Chiari Type I malformation
n
Neurodevelopmental delay, seizures
Hypospadias
n
Seizures

n
n

n
y

2 d.
11 mo.
3 mo.

EPHA4
EPHB4

p.Gly783Ser
p.Glu432fs1

Dmis
Frameshift deletion

Transmitted
Transmitted

Dmis

De novo

29
6 mo.
38

SMARCA2 p.Arg855Leu

n

y

Transmitted

y
n

y
y

n
n
Major depressive disorder with psychotic features, attention deficit
hyperactivity disorder, hydrocephalus, migraines
Cerebral palsy, seizures
n

Transmitted

n

y

Atrial septal defect, partial anomalous pulmonary venous return

n

n

Neurodevelopmental delay, seizures

n
n
n

n
n
n

n
Cystic fibrosis
n

n
n
n
y
n

n
n
n
n
n

n
Attention deficit hyperactivity disorder, recurrent epistaxis
Chiari Type I malformation
n
n

3 mo.

KVGAM44

M

European

Mural

9 mo.

KVGAM45

F

European

Mural

6 mo.

KVGAM49
KVGAM5
KVGAM51

M
M
F

Undetermined
Mexican
European

Mural
Mural
Mural

16 mo.

KVGAM6
VGAM102
VGAM105
VGAM110
VGAM46

F
M
M
F
M

European
European
European
European
European

Mural
Mural
Mural
Mural
Mural

28
31

RASA1

p.Arg709*

ACVR1

p.Asn373Ser

EPHA6

p.Arg259Cys

KEL

p.Gly202Ser

CLDN14 p.Val143Met

35
3 d.
2 mo.

stopgain
T-mis (high CADD =
24.1)
Dmis
T-mis (high CADD =
22.6)

Transmitted
De novo

Dmis

Transmitted

ACVR1

p.Gly39Ser

Dmis

Transmitted

ITGB1

Splice site

splice site

Transmitted

39
1 yr.

Gender M = Male, F = Female; Dmis = Missense variants with 'D' annotation per MetaSVM; T-mis = Missense variants with 'T' or '.' annotation per MetaSVM; y = Yes; n = No
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VI. CLDN14 Knockdown Impairs Vasculogenesis and Brain Vasculature in Xenopus
tropicalis

INTRODUCTION

Recent advances have revealed whole exome wide significant mutations in EPHB4 (Duran
et al., 2018b; Vivanti et al., 2018), de novo chromatin modifying genes, and CLDN14
(Duran et al., 2018b) in patients with Vein of Galen Malformation. It has been proposed
that Vein of Galen Malformation is a phenotypically variable condition with a possible
second hit causing vascular malformations throughout the body, typically capillary
malformations (Duran et al., 2018b). The need for functional validation of whole exome
wide significant findings in genetic studies to determine disease causality is growing
(Neveling et al., 2013). Xenopus tropicalis offer a rapid and easy solution to functional
validation of reported variants. Xenopus lay thousands of eggs which can be easily
manipulated with microinjections of mRNA or CRISPR/Cas9, mature within several days,
and can easily be screened, all at low cost compared to mice (Bhattacharya et al., 2015).

The APJ receptor, also known as msr, is important for both vasculogenesis including the
intersegmental vessels and tail veins (Cox et al., 2006; Devic et al., 1996) and has been
used as an in situ hybridization marker for drug screens testing drugs that effect vasculature
(Cha et al., 2012; Kalin et al., 2009). EPHB4 is a venous vascular marker an important
receptor in determining arterio-venous specification (Wang et al., 1998), the disruption of
which causes arteriovenous malformations in developing animals (Adams et al., 1999) and
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VOGM in humans (Duran et al., 2018b; Vivanti et al., 2018). Helbling and colleagues
demonstrated the EPHB4 and EphrinB2 expression pattern in Xenopus. EPHB4 was
determined to be in the forebrain, midbrain-hindbrain boundary, posterior cardinal vein,
intersomitic veins throughout development with its ligand Ephrin-B2 located in the
hindbrain, somites, and visceral arches (Helbling et al., 1999). A dominant negative,
truncated EPHB4 resulted in abnormal venous vasculature developing into, rather than
between, the somites (Helbling et al. 2000) and recapitulated the phenotypes of Ephrinb2
KO mice (Wang et al., 1998) and Rasa1 mutant mice (Henkemeyer et al., 1995). Less is
known about CLDN14 in Xenopus. Raciti and colleagues found that CLDN14 was
expressed at stage 34 in Xenopus laevis, cousin to X. tropicalis, in the intermediate and
distal duct as well as the head (Raciti et al., 2008).

Xenopus embryos are transparent which allows direct visualization of blood vessels,
especially in the tail which is thin, yet difficult in other regions and organs particularly in
the brain. One of the early attempts to delineate the blood vessels of the brain involved
observing the optic tectum to see the blood vessels and use flowing red blood cells to
confirm their location (Rovainen and Kakarala, 1989). The use of intracardiac FITC
dextran allowed better visualization of patent vessels but it did not allow visualization of
the deeper vasculature (Tiedeken and Rovainen, 1991). The FITC dextran did however
allow researchers to observe the effects of drugs such as adenosine and their antagonists
(Jen and Rovainen, 1994). Levine and colleagues (Levine et al., 2003)created the technique
of intracadiac Dil-Acl-LDL and used their technique to visualize the developing
vasculature from stages 33-46. This technique has been refined and elaborated on by others
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(Ohk and Jung, 2017). Dil-Acl-LDL improved the visualization of deeper vasculature but
it was still limited to relatively superficial vessels that were patent. The creation of Xflk1:GFP transgenic X. laevis (Doherty et al., 2007) allowed direct visualization not only of
patent vessels but the stages of angiogenesis from endothelial cell migration and sprouting
to lumenization. This has greatly improved the ability to live image and study in vivo
vasculogenesis and angiogenesis. However, as embryos develop, it becomes difficult to
visualize deeper vessel structures.

In this thesis, I demonstrate the application and modification of established clearing
techniques (Hama et al., 2015) to improve visualization of the full thickness of the Xenopus
brain vasculature, using the zebrafish vascular map (Isogai et al., 2001) and previous
studies on the optic tectum in Xenopus (Rovainen and Kakarala, 1989; Tiedeken and
Rovainen, 1991) as guides. We generate an in situ probe of CLDN14 for X. tropicalis
examining expression in the whole embryo (Raciti et al., 2008) and in the brain at different
stages of development. Using this new clearing application, we compare the expression of
in situ marker msr as well as the brain vasculature of embryos injected with sgRNA
targeted against RASA1, EPHB4, and CLDN14. Finally, we rescue the CLDN14
CRISPR/Cas9 injected animals with wild type (WT) human CLDN14 compared to the
recurrent patient mutation (Mut) CLDN14 p.V143M(Duran et al., 2018b).

93

RESULTS

EPHB4 and CLDN14 co-immunoprecipitate in vitro
Before beginning our investigation into the effects of knockdown on individual genes in
Xenopus, we wanted to ascertain the relationship between EPHB4 and CLDN14 in vivo.
Human CLDN14 Flag tagged constructs were created, both WT and one with the recurrent
mutation p.Val143Met from Duran and colleagues (Duran et al., 2018b)(see methods).
Combinations of wild type HA-Tag EPHB4 constructs and wild-type vs. mutant CLDN14
constructs were transfected simultaneously into COS-7 cells and immunoprecipitation was
performed (see methods). Both wild type and mutant CLDN14 co-immunoprecipitated
with EPHB4 (Fig. 1).

CRISPR/Cas9 KD of CLDN14 decreased msr expression
CRISPR sgRNAs were synthesized and confirmed to cause double strand cutting (see
methods). Embryos injected with confirmed Cas 9 and CRISPR sgRNAs against RASA1,
EPHB4, and CLDN14 were collected at stage 34 and fixed. In situ hybridization was
performed using in situ marker msr (Fig. 2A). Embryos were scored for normal expression
(ISAs and un-interrupted posterior cardinal vein, Fig. 2B), abnormal (interrupted PCV or
absent/diminished ISAs, Fig. 2C), or absent (lack of any PCV or ISAs, Fig. 2D), and
percentages of all embryos were compared to one another (Fig. 2E). Two-way ANOVA
revealed significant differences in normal, abnormal, and absent expression across
conditions (p<0.0001). Further examination revealed significant decrease in normal
expression of Uninjected Controls (UICs) compared to RASA1 (p=0.0002), EPHB4
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(p<0.0001), and CLDN14 (p<0.0001). There was also significant increase in abnormal
expression of UICs compared to RASA1 (p=0.0015), EPHB4 (p=0.0028), and CLDN14
(p=0.0001) (Fig. 2E) CRISPR/Cas9 injected embryos. There was no significant difference
amongst any conditions with absent expression, and no significant difference amongst
RASA1, EPHB4, and CLDN14 CRISPR/Cas9 injected embryos in either normal or
abnormal expression of msr.

Xenopus brain vasculature
The neural tube of Xenopus tropicalis closes around stages 19-20 and continues to develop
further, becoming a more complex structure with recognizable telencephalon,
mesencephalon, and rhombencephalon structures in the Xenopus after developmental stage
38. The skin is covered by melanocytes (Fig. 3A), which limit the visualization of the
superficial, and most dorsal vasculature, of the brain (Fig. B) preventing direct observation
of the vasculature. The clearing of the animal (Hama et al., 2015)(Hama et al. 2015) and
extraction of the brain allows visualization of the deeper vasculature to the most ventral
side of the brain (Fig. C).

CRISPR/Cas9 KD of VOGM genes causes decreased posterior venous plexus area
Xflk-1:GFP embryos injected with CRISPR/Cas9 against RASA 1, EPHB4, and CLDN14
were collected at stage 47, fixed, cleared, and brains were extracted for confocal
microscopy (see methods). The posterior venous plexus (PVP) develops from the Dorsal
longitudinal vein, the evolutionary precursor to the Median Prosencephalic Vein
(Aurboonyawat et al., 2007). The dorsal most layer of the brain vasculature was analyzed,
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specifically the PVP area (Fig. 4C), and ANOVA one-way test between conditions was
significant (F(6,69) = 4.828, p=0.0004). Further analysis revealed that RASA1
CRISPR/Cas9 injected animals showed significant increase in the PVP area compared to
UICs (p= 0.0160), Cas9 only injected animals (p=0.0223), and CLDN14 CRISPR/Cas9
injected animals (p=0.0357) (Fig. 4E). There were no other significant differences between
conditions. Attempts at rescue the PVP area with wild type (WT) vs. mutant V143M (Mut)
human CLDN14 mRNA were not successful, with no significant differences either
compared to UIC, Cas9, CRISPR/Cas9 of CLDN14, or compared to each other.

CRISPR/Cas9 KD of VOGM genes causes decreased Mesencephalic Vein Length
The Mesencephalic Vein (MSV) makes up part of the deep venous drainage system in
mammals, and helps drain blood from the VOGM in affected patients. The MSV lengths
(Fig. 4 B) of CRISPR/Cas9 injected animals were compared and ANOVA one-way test
between conditions was significant (F= 16.76, p<0.0001). Further analysis demonstrated
significance of conditions for RASA1, EPHBB4, and CLDN14 CRISPR/Cas9 injected
animals compared to both UIC (RASA1 p<0.0001; EPHB4 p<0.0001; CLDN14 p=0.0006)
as well as Cas9 only (RASA1 p<0.0001; EPHB4 p<0.0001; CLDN14 p=0.001) (Fig. 4D).
There was no significant difference between UIC (p=0.5377), nor Cas9 only (p=0.5307),
compared to CLDN14 CRISPR/Cas9 + WT mRNA. However, the same was true for
CLDN14 CRISPR/Cas9 + Mut mRNA, and there was no significant difference either
between the WT mRNA or Mut mRNA injected conditions, nor CLDN14 CRISPR/Cas9
alone compared to CLDN14 CRISPR/Cas9 + WT vs. Mut mRNA. No other significant
differences between conditions
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DISCUSSION

This work suggests an interconnection between EPHB4 and CLDN14 and the similar
impact they each have on developmental vasculature, strengthening their implication in
VOGM. When compared to the known gene, RASA1, both EPHB4 and CLDN14
demonstrated similar effects on abnormal vasculogenesis as measured by in situ marker
msr. However, it remains unclear whether or not they are acting along the same pathway
or mechanism, or if they are completely independent pathways.

Previous work using EPHB4 morpholino in zebrafish noted abnormalities in both the
dorsal longitudinal vein, with duplication or increased size/area, and the MSVs with either
narrowing, absence, or duplication (Vivanti et al., 2018). Although we observed
differences of UIC and Cas9 compared to CRISPR/Cas9 injected animals (not shown),
namely more deranged vasculature in CRISPR/Cas9 injected animals, in this work we
attempted a more quantitative rather than observational approach. Additionally,
CRISPR/Cas9 injection of EPHB4 and CLDN14 also decreased MSV length in a similar
fashion to RASA1. However, there was no significant difference between CRISPR/Cas9
injections of EPHB4 or CLDN14 compared to UIC or Cas9 only for the PVP, which is the
more relevant as the evolutionary precursor to the Median Prosencephalic Vein which is
associated with VOGM (Aurboonyawat et al., 2007). On the contrary, RASA1
CRISPR/Cas9 injected animals had significantly increased PVP area, compared to UIC,
Cas9, and CLDN14 CRISPR/Cas9 injected animals, suggesting increased angiogenesis and
abnormal vasculature.

97

Coinjection of CLDN14 CRISPR/Cas9 with either WT or Mut mRNA failed to rescue the
PVP area or MSV length when compared to CLDN14 CRISPR/Cas9 only injected
embryos. This is likely due to insufficient data to make meaningful comparisons and
analyses. Future investigation will continue to compare the brain vasculature, and perhaps
the vasculogenesis using in situ hybridization as well.

The lack of significant findings may be due to the limitations of the Xenopus model and
difficulties extracting and imaging the brains (see below) which contributed to the low
number of replicates for all CLDN14 conditions, with or without mRNA, with ranges of
n=1-8 for all conditions in examining the MSV lengths and PVP area. Although
CRISPR/Cas9 successfully causes double strand breaks and subsequent knockout of
candidate genes using the methods applied here, the cutting efficiency is not 100%
throughout all cells and is instead mosaic (Bhattacharya et al., 2015). This may contribute
to the range of findings in CRISPR/Cas9 injected animals’ PVP area as the CRISPR/Cas9
double stranded break is not always certain to occur in cells in vascular and endothelial
lineages.

Evidence of EPHB4 and CLDN14 interactions
Claudins have been shown to be associated with and interact with various ephrins and Ephs.
Both claudin-1 and claudin-4 are co-localized with ephrin-B2 and EphB2 on the cell
surface of adhering epithelial cells which come into contact in the midline (Dravis and
Henkemeyer, 2011). This interaction was impaired in ephrin-B2-Beta-gal fusion
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suggesting a possible extracellular (Dravis and Henkemeyer, 2011). EPHA2 has been
shown to associate with Claudin-4 extracellularly which allows EPHA2 to phosphorylate
Claudin 4 intracellularly at Tyr-208, thereby increasing paracellular permeability (Tanaka
et al., 2005a). Furthermore, binding of claudins to cause cell-cell interactions has also been
associated with the interaction between claudins as well as induction of EPH
phosphorylation (Tanaka et al., 2005b).

Our findings contribute to the growing evidence of a connection between EPHB4 and
RASA1. The co-immunoprecipitation of WT EPHB4 and both WT and Mut CLDN14
suggest some yet unknown interaction. The significant findings of abnormal
vasculogenesis and MSV length further lend to this connection. CLDN11 was recently
found to interact only with EphrinB2 on osteoclasts but was found to only interact with
EPHB4 on osteoblasts (Baek et al., 2018). While the various motifs and mechanisms that
allow the specific interaction between CLDN14 and EPHB4/ Ephrin B2, is not well known,
our results from co-IP indicate that this interaction is possible and merits further
investigation.

Limitations of the Xenopus model
We found that the use of the zebrafish brain vascular map served as a useful guide for
studying the brain vasculature of Xenopus tropicalis (Isogai et al., 2001). There were
however still difficulties with assuring the identity of the different vessels. Xenopus offer
several difficulties in observing brain vasculature: 1) melanocytes which overly the brain,
2) auto-fluorescence, 3) extraction of brains, and 4) mounting. Melanocytes which overly
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the brain vasculature are the foremost problem in observing the brain vasculature. The
melanocytes are more concentrated over the brain and early spinal cord, blocking direct
observation of vessels in vivo. While melanocytes could be removed with other methods
including PTU (Milos and Dingle, 1978), or direct light exposure on a light box for 4 hours
(direct observation made by lab colleague), however these might cause unknown
consequences on the brain vasculature or reduce the GFP signal.

The high background fluorescence generated in Xenopus (Lee and Bezanilla, 2019),
though more prominent in the tailbud stages, still remains slightly during stages 46-47
when our observations were made. The green fluorescent background, in combination with
the proteins and cellular contents, prevented visualization of deeper vasculature structures
in vivo. The use of clearing techniques (Hama et al., 2015)) removed the fluorescent
background without effecting the GFP signal and thereby allowed visualization of the full
thickness of the brain and all the brain’s vasculature. Due to the round head of dorsal aspect
of the Xenopus embryo, we extracted brains from fixed embryos at stages 46-47. However,
with extraction of the brain, the tissue of skin would often fuse to the brain tissue overlying
the 4th ventricle which also contained the vessels. Removal of the brains would often
incidentally de-roof the 4th ventricle thereby destroying the vessels of interest in the
process. Finally, to observe all levels of the brain vasculature, dorsal to ventral, we
mounted brains between two coverslips using Dow Corning high vacuum grease so as not
to completely flatten the brains and still visualize the 3D structure. However, there was no
way to standardize this approach and so some brains may have been more compressed than
others.
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We attempted the use of optical coherence tomography (OCT) to observe vessels in vivo
both in the tail and in the brain. OCT can provide resolutions similar to histology but in a
fraction of the time or effort (Huang et al., 2015). While standard Doppler allowed good
visualization of the heart, outflow tract, and dorsal artery and both dorsal and ventral veins
of the tail, it did not allow adequate visualization of the remaining smaller tail vessels.
Vessels on the dorsal aspect of the brain were also unable to be visualized due to the small
caliber, thinness as they overly the comparatively vast 4th ventricle of the brain. Though
we did not attempt it in this study, OCT may be better suited at assessing the downstream
impact of candidate gene knockout on blood flow to the brain by examining changes in the
size of ventricles and the parenchyma itself as has been done by our group studying
candidate hydrocephalus genes in Xenopus tropicalis (data not yet published).

Future work studying the vasculature of brain below the most dorsal aspect necessitates
further techniques. The use of a combined flk1:GFP and albino model may solve the issue
of melanocytes but will not address the issue of auto-fluorescence preventing the
observation of deeper structures. Future work may also benefit from a mammalian model
to more specifically address the effects on the vein of Galen proper in heterozygous
animals, as many patients presented with inherited mutations (Duran et al., 2018b) rather
complete knockdown with CRISPR/Cas9,
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MATERIALS AND METHODS

CRISPR/Cas9 design and creation
CRISPRs will be designed as previously described (Deniz et al., 2018). CRISPRs are
designed by a combination of CRISPRscan.org (Doench et al., 2016; Moreno-Mateos et
al., 2015) and UCSC genome browser (Kent et al., 2002) by selecting a CRISPR with a
high score (>60), targets an early exon, few off targets by All (Hsu et al., 2013) or Seed
(Cong et al., 2013), and a low CFD (Doench et al., 2016). The final CRISPR sequence
created is 5’-CTAGCTAATACGACTCACTATAGG - n(18) target sequence GTTTAGAGCTAGAAATAGCAAG-3’as previously described (Bhattacharya et al.,
2015). CRISPR sgRNA primers can be seen in Table 1. The CRISPR is created by
following the protocol of the EnGen sgRNA synthesis kit (NEB). RNA is purified using
the Zymo RNA Clean and Concentrator kit. The CRISPR concentration is measured by
NanoDrop, diluted, and stored at -80C. Cas9 Protein was ordered from PNA-Bio (Item
#CP01) and eluted to stock concentration of 2 ng/nL. We inject Cas9 protein at a
concentration of 1.6ng/ embryo.

Constructs
Human CLDN14 was obtained from the hORFeome v8.1 (HsCD00512723) (Yang et al.,
2011). Plasmids were transformed into XL10 gold cells. A miniprep was performed from
the cultured colonies using the Qiagen miniprep kit and then sequenced using T7 and Sp6.
Gateway cloning was performed using standard procedures using Gateway LR Clonase II
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Enzyme mix (Invitrogen) into pDEST vectors, with or without mCherry. Sequence was
confirmed by Sanger sequencing.

Patient mutations were created using the Q5 Site-directed mutagenesis kit and primers
designed using the NEB Base Changer online tool http://nebasechanger.neb.com/. Primers
can be found in Table 1. Point mutations were confirmed by sequencing. WT and mutant
mRNA was created from the WT and point mutated vectors respectively using the
mMessage mMachine kit (Ambion), nanodroped, diluted, and stored at -80C in aliquots
for injection. Vectors were transformed into XL10 gold cells. Selected colonies were
further grown overnight before DNA extraction using the Qiagen miniprep kit, purified,
and sequenced to confirm point mutation.

Animal Husbandry and In Vitro Fertilization
X. tropicalis were housed and cared for in our aquatics facility according to established
protocols that were approved by our local IACUC (Bhattacharya et al., 2015). In vitro
fertilization was performed as previously described (del Viso and Khokha, 2012).

Microinjection
Reaction mix, composed of CRISPR, Cas9 protein, and tracer, is prepared as previously
described and 2nL is injected per embryo (Deniz et al., 2018). Total CRISPR sgRNA dose
is titrated per gene targeted to be between 50ng to 500ng (Blitz et al., 2013; Guo et al.,
2014; Nakayama et al., 2013). Injected embryos were kept at 28C for 2 hours after injection
to ensure CRISPR/Cas9 efficiency before being raised at 25 C until desired stages.
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Similarly, mRNA and tracer reaction mix is prepared to also inject 2nL per embryo at the
1 cell stage. mRNA is also titrated for rescue up to 500ng total per embryo. Rescue
experiments had embryos injected with 2nL of CRISPR/Cas9 mix followed by 2nL of
mRNA mix. Embryos were examined for tracer 4-12 hours after injection. Embryos that
did not display the tracer were euthanized and discarded.

In situ hybridization probes
A CS107 plasmid containing msr, originally from the sanger library (clone ID#
Tneu054M15) was transformed into XL10 gold cells (Agilent Technologies). A miniprep
was performed from the cultured colonies using the Qiagen miniprep kit. Minipreps were
sequenced using the Sp6 and T3 reverse. After sequence confirmation, plasmid was
linearized with restriction enzymes, flanking the inserted msr sequence, for at least 2h at
37C. DNA was cleaned using RNAse free Qiagen PCR Purification kit. Anti-sense rna
probe was created using the HiScribe T7 High Yield RNA synthesis kit (NewEngland
Biolabs). RNA was purified with Zymo Clean and Concentrator kit. Anti-sense RNA probe
concentration was determined by nanodrop before dilution and storage at -80C in aliquoted
concentration.

CLDN14 probe was created de novo for X. tropicalis. X. tropicalis cDNA was obtained
using the SuperScript III kit (ThermoFischer). Primers for CLDN14 were created (see
Table 1) using the Primer BLAST (NIH website). CLDN14 sequence was amplified by
PCR using the Phusion High Fidelity DNA Polymerase (M030, NEB) and PCR product
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was run on a 1.6% agrose gel to confirm sequence amplification. CLDN14 sequence was
cloned using the Zero Blunt TOPO Blunt End kit (ThermoFischer). Colonies were
amplified, minipreped, sequenced, and probe was created as detailed above.

Whole Mount In situ hybridization
Embryos were fixed in Memfa solution and then dehydrated with 100% ethanol and stored
at -20C until in situ hybridization was performed. In Situ hybridization was performed on
embryos as previously described (Khokha et al., 2002). In situ hybridization was performed
by a semi-automated process using the Biolane HT1 16V machine (Intavis Bioanalytical
Instruments). Embryos were developed in BM Purple at 4C or room temperature until
signal was adequately visible. When mature, the in situ hybridization was stopped with 1x
Maleic Acid Buffer washing for 5 minutes, followed by fixation with Bouin’s Solution for
1 hour, washed with 1x Standard Saline Citrate (SSC) until the yellow staining was
removed. Embryos were then bleached in a solution containing 1% hydrogen peroxide, 5%
formamide, 1x SSC on a light box for 1 hour to remove pigments. Bleaching was stopped
by washing in 1x SSC twice.

Confirming CRISPR cut T7 endonuclease reaction
CRISPR/Cas9 injected and uninjected control (UIC) embryos were collected at stage 40.
DNA was extracted using the Qiagen Blood and Tissue kit and stored. Gene targets were
amplified by PCR using primers flanking the targeted cut site and Phusion High Fidelity
DNA Polymerase kit (M030, NEB). The T7 endonuclease reaction was performed as
previously described (Guschin et al., 2010), to ascertain CRISPR/Cas9 cutting.
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Clearing of Embryos
Embryos were collected at stage 47 and fixed in 4%PFA. Fixed embryos were washed
twice with 1x PBS and then placed in Scale-S4 (Hama et al., 2015) for 2 days at 4°C on a
rocker. This cleared the embryo of pigments without degrading the fluorescent signal. After
clearing, embryos were washed with 1xPBS twice and stored at 4°C until dissection and
mounting for microscopy.

Confocal Imaging
Brains were extracted from cleared embryos, placed on a coverslip slide. Prolong antifate
gold reagent (Invitrogen) was used to prevent degeneration of GFP signal. Dow Corning
high vacuum grease was placed at the corners of the coverslip slide before placing onto the
slide to prevent complete squashing of the dissected brain.

Confocal microscopy was performed using the AireScan microscope. Full thickness Zstack images were obtained of extracted brains. Images were processed to adjust brightness
and contrast, and analyzed for their posterior venous plexus area and mesencephalic vein
length.
ImageJ was used to stitch and analyze images.

Cell Culture
COS-7 cells Cos-7 (COS) cells were passaged at 80–90% confluence on high glucose
DMEM (Dulbecco’s modified Eagle’s medium, Gibco Life Technologies) supplemented
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with 10% fetal bovine serum (FBS, Gibco Life Technologies), L-glutamine, and
penicillin/streptomycin.

Mutagenesis of CLDN14 and Plasmid Transfection
A wild-type human CLDN14 cDNA was sub-cloned into pShuttle-IRES-hrGFP-2 plasmid
vector with Flag-Tag sequence. The QuikChange II Site-Directed Mutagenesis Kit
(Aligent Technologies, Santa Clara CA, USA) was used to generate isolated single aminoacid changes within the CLDN14 ORF (Val143Met). All mutant constructs were sequenced
to confirm successful mutagenesis. The wild-type EPHB4 construct used previously
(Duran et al., 2018b) and either wild-type CLDN14, mutant construct, or empty vector were
both transiently transfected into COS-7 cells using Lipofectamine 2000 transfection
reagent (Invitrogen, Carlsbad, CA, USA) according to its standard protocol. DNA
complexes were removed after 5 h and replaced with fresh complete medium. After 48
hours, the medium was aspirated and the cells starved for 18 h in serum-free conditions.

Co-immunoprecipitation and Western Blotting
Cell lysates were prepared using NP40 lysis buffer (50 mM Tris, pH7.5; 1% Nonidet P-40;
150 mM NaCl; 10% Glycerol) containing protease and phosphatase inhibitor cocktail
(Roche, Basel, Switzerland). Protein concentrations were measured with DC Protein Assay
Reagents (Bio-Rad, Hercules CA, USA). For immunoprecipitation, equal amounts of cell
lysates were incubated with Sepharose beads linked to anti-HA-Tag antibody (Cell
Signaling Technology, Danvers, MA, USA) overnight at 4 °C. Immunoprecipitated protein
complexes were separated on SDS-PAGE gel and analyzed by Western blotting using anti-
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HA-Tag and anti-Flag-Tag (Cell Signaling Technology, Danvers MA, USA), anti-Ras
GAP (Santa Cruz Biotechnology, Dallas TX, USA). Band intensities were quantified using
ImageJ software (Schneider et al., 2012). Statistical analyses were performed using Prism
7 software (GraphPad Software, La Jolla CA, USA).

Statistics
Statistical analyses were performed using Prism 7 software (GraphPad Software, La Jolla
CA, USA).

Attribution of work
Jonathan R. Gaillard was trained in and performed Xenopus tropicalis IVF, CRISPR
sgRNA design, creation, and confirmation using the T7 endonuclease reaction in the labs
of Dr. Mustafa Khokha and Dr. Engin Deniz. JRG generated in situ hybridization probes
and performed in situ hybridization experiments, injected embryos with CRISPR/Cas9
with or without mRNA, fixed and cleared embryos, extracted brains, and mounted them
for imaging with the help of Dr. Deniz. JRG and Dr. Deniz performed the confocal imaging
of the brains.

Cell work and western blotting was performed by Bogdan Yatsula, Alan Dardic, and Jinwei
Zhang.
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FIGURES
Figure 1. Co-Immunoprecipitation reveals interaction between EPHB4 and CLDN14
Representative immunoblot showing effects of Ala509Gly, Lys650Asn, and Phe867Leu
mutations on WT EPHB4 and CLDN14 in Cos-7 cells, analyzed by immunoprecipitation
(IP) with HA-Tag antibody followed by immunoblot (IB) with HA-Tag and Flag-Tag
antibodies. Blot demonstrates EPHB4 co-immunoprecipitation with both wild type and
mutant Val143Met CLDN14
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Figure 2. msr expression is decreased in CRISPR/Cas9 injected embryos
In situ hybridization was performed using marker msr on Uninjected Control (UIC) and
embryos with Cas9 and CRISPR sgRNA targeted against RASA1, EPHB4, and CLDN14,
that were raised to stage 34. (A) msr is localized to the developing endothelium and
vasculature and allows the visualization of the Viteline Vein Network (VVN), where early
hematopoiesis is located, the Posterior Cardinal Vein (PCV, arrows), and sprouting and
growth of the Intersegmental Arteries (ISA, arrow heads). For the purposes of scoring only
the head and the VVN were not used, and only the tail and body were used (dashed box).
Embryos were scored as (B) normal expression with ISAs formed or sprouting (arrow
head) and un-interrupted PCV (arrow), (C) abnormal with interrupted PCV (arrow) or
absent/diminished ISAs (arrow head), or (D) absent with lack of any PCV(arrow) or ISAs
(arrow head). (E) Embryos were scored data collected for the percentage of embryos
displaying normal, abnormal, or absent expression and found to be significant by two-way
ANOVA comparing both expression (normal, abnormal, and absent) and conditions (UIC,
RASA1, EPHB4, CLDN14), with p<0.0001. Significant findings for abnormal expression
UIC and CRISPR/Cas9 are noted (E). **: p<0.01; ***: p<0.001

110

Figure 2. msr expression is decreased in CRISPR/Cas9 injected embryos
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Figure 3. Clearing allows visualization of full thickness brain vasculature
(A) The stage 47 Xenopus tropicalis embryo has prominent melanocytes covering the
dorsal aspect of the animal from anterior to posterior, including the head (red oval). (B) In
Xflk1:GFP embryos, melanocytes obstruct the view of the dorsal vasculature of the brain.
Additionally, deep vasculature is unable to be visualized. (C) Clearing of the animal and
subsequent extraction of the brain allows full visualization of the entire thickness of the
brain vasculature, here presented with three z-stacks of the dorsal most vessels, the middle
vessels, and the ventral vessels.
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Figure 4. CRISPR/Cas9 KD decreases Mesencephalic Vein length and Posterior
Vascular Plexus area
(A) Stage 47 Xflk1:GFP embryos for uninjected control (UIC), Cas9 only, CRISPR/Cas9
against RASA1, EPHB4, and CLDN14, and coinjected CLDN14 CRISPR/Cas9 and wild
type (WT) vs. mutant (Mut) were collected, fixed, and cleared. Brain were removed and
mounted for confocal microscopy imaging. (B) The Mesencephalic Vein (MSV, green line)
and the (C) Posterior venous plexus (PVP, red area) were measured and compared across
conditions using ImageJ. (D) One-way ANOVA demonstrated significance across
conditions for MSV length (F= 16.76, p<0.0001). Further analysis demonstrated
significance between RASA1, EPHBB4, and CLDN14 CRISPR/Cas9 injected animals
compared to both UIC, as well as Cas9 only. (E) Similarly, one-way ANOVA
demonstrated significance across conditions for PVP area ( F(6,69) = 4.828, p=0.0004).
Further analysis revealed that RASA1 CRISPR/Cas9 injected animals showed significant
increase in the PVP area compared to UICs (p= 0.0160), Cas9 only injected animals
(p=0.0223), and CLDN14 CRISPR/Cas9 injected animals (p=0.0357).
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Figure 4. CRISPR/Cas9 KD decreases Mesencephalic Vein length and Posterior
Vascular Plexus area

114

SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure 1. T7 endonuclease confirms cutting by sgRNAs
Embryos that were uninjected controls (UIC) or injected with sgRNA/Cas9 for RASA1,
CLDN14, and EPHB4, and PCR amplified around the target region of the sgRNA.
Application of T7 endonuclease reveals additional bands in sgRNA/Cas9 injected animals
but not in uninjected control animals.
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Supplementary Table 1. Nucleotide sequences used
sgRNA design for CRISPR/Cas9
Gene

Sequence

RASA1

taatacgactcactataGGGAGGTGGCGAGGCGACATgttttagagctagaa

EPHB4

taatacgactcactataGGGAGAATGGGCCAAACCGGgttttagagctagaa

CLDN14

taatacgactcactataGGGGGGCTATCGGTGATCGGgttttagagctagaa
Primers used for T7 fragment analysis

Gene

Forward Sequence

Reverse Sequence

RASA1

CGGAAGCTGCCACTGATCTAA

TGTTTGGGACCCGGGATAAG

EPHB4

TGGCTTCTACTTGGCGTTCC

AGTCAGACAACCACACCACC

CLDN14

CCTCATTGGCTTCATCGGGA

TGCTTTTGTTGACGGGCTG

Primers used for Q5 site directed mutagenesis
Gene

Forward Sequence

Reverse Sequence

CLDN14

CACCAACGACaTGGTGCAGAACTTC

GTCCAGGAGACGGCCACC

Primers used to design Xenopus tropicalis in situ probe
Gene

Forward Sequence

Reverse Sequence

CLDN14

TGGCATACATGAAGGGCCTG

TTGCTTTTGTTGACGGGCTG
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